

AUSTRALIAN NATIONAL DIABETES AUDIT
2021
Supplement

Contents

Acknowledgements	2
Abbreviations and Acronyms	3
1. Origins of the ANDA Dataset	4
2. Data Queries	5
3. Data Assumptions, Decisions and Manipulations	6
4.1 Frequency Count Data (Adults)	7
4.2 Frequency Count Data (GDM)	17
4.3 Frequency Count Data (Paediatrics)	27
5.1 Missing Data (Adults)	37
5.2 Missing Data (GDM)	39
5.3 Missing Data (Paediatrics)	41
6.1 Descriptive Report (Adults)	43
6.2 Descriptive Report (GDM)	101
7. Historical Comparison of Pooled Data (Adults)	104
8. Diabetes Publications & Resource List 2020	107
9. References	123

Acknowledgements

ANDA-AQCA 2021 has been supported by funding from the Australian Government Department of Health.

ANDA Project Executive

Professor Sophia Zoungas - Project Lead
Ms Dimitra Giannopoulos - Project Manager/Secretariat
A/Professor Susannah Ahern – Technical Advisor
A/Professor Arul Earnest - Senior Biostatistician
Dr Farhad Salimi - Data Analyst
Dr Luke Cieslik - Clinical Research Fellow
Dr Lavanya Gupta - Clinical Research Fellow
Dr Anthony Pease – Clinical Researcher
Ms Trieu-Anh Truong - Data Management Officer
Mr Matthew Quigley – PhD Candidate

ANDA Scientific Advisory Committee

Professor Sophia Zoungas - Chair
A/Professor Sofianos Andrikopoulos
A/Professor Wendy Davis
Professor Barbora deCourten
Professor Jeff Flack
Professor Jenny Gunton
Dr Konrad Kangru
Ms Megan Phelan
Ms Sally Rayner
Professor Jane Speight
Ms Natalie Wischer
Professor Jencia Wong

We would like to thank the participating diabetes services and their patients for their generous contribution to this work.

We gratefully acknowledge the significant support and championing of this project over many years by the NADC, a division of the ADS.

In the spirit of reconciliation, we acknowledge the Traditional Custodians of country throughout Australia and their connections to land, sea and community. We pay our respect to their Elders past and present and extend that respect to all Aboriginal and Torres Strait Islander peoples today.

Abbreviations and Acronyms

ACE	Angiotensin Converting Enzyme
ANDA	Australian National Diabetes Audit
AQCA	Australian Quality Clinical Audit
ATSI	Aboriginal and Torres Strait Islander
ARB	Angiotensin II Receptor Blockers
BMI	Body mass index
BP	Blood pressure
CABG	Coronary artery bypass graft
DVA	Department of Veterans Affairs
eGFR	Estimated glomerular filtration rate
GDM	Gestational diabetes mellitus
HbA _{1c}	Glycated haemoglobin
HDL	High density lipoprotein
IQR	Interquartile range
LDL	Low-density lipoprotein
NDOQRIN	National Diabetes Outcomes Quality Review Initiative
NDSS	National Diabetes Services Scheme
NICE	National Institute for Health and Care Excellence
SD	Standard deviation
T1DM	Type 1 diabetes mellitus
T2DM	Type 2 diabetes mellitus

1. Origins of the ANDA Dataset

There has been longstanding worldwide interest in developing suitable diabetes datasets and methods of data collection to capture appropriate diabetes outcomes for quality improvement. As a result, collection, analysis and reporting of standardised diabetes datasets is now widely practised. The European Association for the Study of Diabetes (EASD) Study Group DO IT (Diabetes care Optimisation through Information Technology)⁽¹⁾ undertook much work aimed at improving the quality of diabetes care through the appropriate use of information technology, including promoting the collection, analysis and reporting of the DiabCare dataset^(2, 3) for audit and benchmarking purposes. From this has come the DiabCare Q-Net initiative⁽⁴⁾.

A similar initiative, the NSW Diabetes Outcomes Workshop (NDOW), was undertaken in Australia in September 1993 with funding from the NSW Health Department^(5, 6). Forty-five stakeholders including diabetes health professionals, Health Department officials and consumers met for a one-day workshop and agreed on a dataset of 59 health outcome data elements that covered demographic, acute and chronic complications and self-care practice areas of diabetes care. These items became known as the NDOW dataset, and subsequently these data items have become widely promulgated for collection (using standardised definitions) across Australia.

In 1997 the Australian Diabetes Society (ADS) Council accepted a recommendation to adopt the NDOW dataset as its Diabetes Outcomes dataset, and formed a sub-committee (now named the National Diabetes Data Working Group (NDDWG)). This sub-committee managed the dataset and promoted quality diabetes care in Australia, through the National Diabetes Outcomes Quality Review Initiative, (NDOQRIN). The NDDWG has taken a subset of the NDOW dataset and has promoted its collection as a minimum dataset (for quality diabetes care) in a variety of clinical practice settings.

After diabetes was named the 5th National Health Priority Area in 1996⁽⁷⁾, work followed to improve diabetes care in Australia including the commissioning of the National Diabetes Strategy to update and replace the National Action Plan. One aspect reviewed was the need for local data on which appropriate planning could be carried out and assessment of the effect of initiatives could be undertaken. Consequently, several initiatives indicated the need for reliable data in Australia (including diabetes indicators work), as noted in the National Health Priority Areas Report: Diabetes Mellitus 1998⁽⁷⁾. However, data on clinical aspects of diabetes, including outcomes data, were deficient in Australia as highlighted in The National Diabetes Strategy and Implementation Plan report¹².

The NDDWG continued to promulgate the NDOQRIN dataset, and in 2002 was successful in having it accepted as the first clinical dataset to be included in the National Health Data Dictionary and Knowledgebase, Version 12. This dataset has since been enhanced, and is now online as part of the AIHW – Metadata Online Registry ('METeOR') as the Diabetes (clinical) Data Set Specification⁽⁸⁾.

The NDOQRIN minimal dataset was utilised for the inaugural ANDA data collection in 1998 (then known as the Australian National Diabetes Information Audit & Benchmarking, ANDIAB). Subsequent enhancements have been made on a biennial basis to incorporate new research on diabetes quality clinical indicators, and to address feedback from centres participating in the previous audit cycle. The ANDA dataset has been reviewed for consistency with international datasets for diabetes benchmarking. There are high rates of agreement between the ANDA dataset and international diabetes benchmarking datasets, including the Diabetes Quality Indicators Project in the US⁽⁹⁾, the National Board of Health and Welfare Quality Indicators in Sweden⁽¹⁰⁾, and the National Institute for Health and Care Excellence Diabetes Quality Indicators in the United Kingdom⁽¹¹⁾.

2. Data Queries

Missing vital data fields:

A list was generated of all instances of missing data in any of the following fields: Sex, date of birth, year of diagnosis, diabetes type, diabetes management, height, weight, initial visit, fasting status (if lipids recorded).

Potentially invalid data values:

A list was generated to check potential data inaccuracies as follows:

- (1) Male = Pregnant OR Female <18 or >55 = Pregnant
- (2) Type 1 and insulin not indicated
- (3) GDM and not currently pregnant
- (4) Year of Diagnosis or Year Started Insulin < Date of birth
- (5) On Insulin since - Year < Date of diagnosis
- (6) Systolic BP < diastolic BP OR systolic or diastolic is missing
- (7) Systolic BP <70mmHg or >200mmHg OR diastolic BP <40mmHg or >130mmHg
- (8) Age >18 years and height <1.3 metres or >2.2 metres
- (9) Age >18 years and weight <40 kilograms or >200 kilograms
- (10) BMI >50 kg/m²
- (11) Age >18 years and BMI <15
- (12) Type 1 and on insulin ≥3 years after date of diagnosis
- (13) Age <2 years

Whilst some of the scenarios may be possible (e.g. 7, 8, 9), the likelihood is that they represent incorrect data recording or interpretation by the computer system.

Possible duplicates: (double individual registration/data entry), based on sex and date of birth match.

Potentially incorrect HbA_{1c}, lipid, and creatinine values: HbA_{1c} <4%, HbA_{1c} <20 mmol/mol, total cholesterol <2.0 mmol/L, HDL cholesterol >2.5 mmol/L, triglyceride <0.5 mmol/L, creatinine <50 or >1000 µmol/L.

3. Data Assumptions, Decisions and Manipulations

As in previous years, data assumptions and decisions were made based on the following rules.

Only patients aged 18 and above were included in the pooled analysis. In 2021, the results of patients with GDM and patients under 18 years were presented separately.

Missing data were also calculated conditionally where relevant:

- Date of visit=1/06/2021 if missing
- Pregnancy=Yes, if female and has GDM
- Insulin=Yes, if insulin duration and/mode indicated

Invalid data were excluded:

- Date of birth after visit date
- Pregnancy if male or female aged >55
- Urinary protein/albumin value, if units not indicated
- Type 1 and insulin use not indicated, unless < 12 months since diagnosis
- 'Year of diagnosis' and 'Insulin duration' excluded if < date of birth

Data manipulations and derivation

- Duration of diabetes was calculated: Audit year - Year of diagnosis
- Where diabetes was type 1, age at diagnosis was ≥ 40 , insulin was commenced >3 years after diagnosis and BMI was ≥ 25 , a diagnosis of type 2 diabetes was assigned
- Anti-hypertensive therapy changed to 'No' if no medications were indicated
- 'Diet only' changed to 'No' if other management methods details were indicated
- 'Lipid lowering therapy' changed to 'No' if no therapy details were indicated
- BMI was calculated: $\text{weight (kg)} / \text{height (m)}^2$
- eGFR was calculated using the CKD-EPI equation
- Urinary protein/albumin assessment was considered in relation to published guidelines for laboratory thresholds
- Instances where patients reported multiple modes of insulin, the following hierarchical algorithm was used:
Hybrid closed loop system > Pump > Basal bolus > Pre-mixed > Basal

Descriptive Reports

The descriptive reports provide a breakdown of data by diabetes type for patient characteristics and outcomes. Raw data are demonstrated in tabular or descriptive format, and the corresponding bar charts demonstrate the mean or percentage by collection site. In each bar chart, individual bars across the x-axis represent a single data collection site, and the y-axis corresponds to the mean or percentage at the individual site for that characteristic. The bars are presented in descending order, with the data from a site with the highest mean or percentage presented on the left. Note that there are variable numbers of bars across different charts - as data for certain characteristics were not recorded at every site. At the site level, the distribution of key clinical outcomes appeared normally distributed and therefore the means (as opposed to medians) were utilised in the descriptive reports.

4.1 Frequency Count Data (Adults)

SECTION 1. PATIENT DEMOGRAPHICS (ADULTS)

Item	Field	Category	Total	%	Relative %*	Median	Mean	SD	Min	Max
1.1	Date of birth	DOB	4484	100.0%	100%					
		Missing	0	0.0%						
		Sum	4484	100%	100%					
Age	Age (years)		4484	100.0%	100%	60.8	57.6	17.3	18.0	93.9
		Missing	0	0.0%						
		Sum	4484	100%	100%					
1.2	Sex	Male	2418	53.9%	54.5%					
		Female	2017	45.0%	45.5%					
		Missing	49	1.1%						
		Sum	4484	100%	100%					
1.2.1	Currently pregnant (females aged 18-55 years)	Yes	49	5.6%	5.7%					
		No	806	92.4%	94.3%					
		Missing	17	1.9%						
		Sum	872	100%	100%					
1.3	Date of visit	Visit Date	4484	100.0%	100%					
		Missing	0	0.0%						
		Sum	4484	100%	100%					
1.4	Initial visit	Yes	610	13.6%	14.0%					
		No	3750	83.6%	86.0%					
		Missing	124	2.8%						
		Sum	4484	100%	100%					
1.5	Aboriginal/Torres Strait Islander	Yes	154	3.4%	3.5%					
		No	4244	94.6%	96.5%					
		Missing	86	1.9%						
		Sum	4484	100%	100%					
1.6	Country of birth	Country	4395	98%	100%					
		Missing	89	2.0%						
		Sum	4484	100%	100%					
1.7	NDSS member	Yes	4038	90.1%	94.0%					
		No	256	5.7%	6.0%					
		Missing	190	4.2%						
		Sum	4484	100%	100%					
1.8	DVA patient	Yes	58	1.3%	1.3%					
		No	4269	95.2%	98.7%					
		Missing	157	3.5%						
		Sum	4484	100%	100%					

*Relative % = % of the total excluding the missing values

SECTION 2. DIABETES TYPE & MANAGEMENT (ADULTS)

Item	Field	Category	Total	%	Relative %*	Median	Mean	SD	Min	Max
2.1	Year of diagnosis	Year	4358	97.2%	100%					
		Missing	126	2.8%						
		Sum	4484	100%	100%					
		Duration of diabetes								
	Duration (years)	Duration (years)	4324	96.4%	100%	14.0	16.0	11.8	0.0	68.0
		Missing	160	3.6%						
		Sum	4484	100%	100%					
		Type of diabetes								
2.2	Type of diabetes	T1DM	1304	29.1%	29.2%					
		T2DM	3025	67.5%	67.7%					
		GDM	0	0.0%	0.0%					
		Don't know	26	0.6%	0.6%					
		Other	110	2.5%	2.5%					
		Missing	19	0.4%						
		Sum	4484	100%	100%					
2.3	Blood glucose monitoring	None	336	7.5%	7.6%					
		Finger pricking**	3440	76.7%	77.5%					
		Continuous glucose monitoring**	373	8.3%	8.4%					
		Flash glucose monitoring**	405	9.0%	9.1%					
		Missing	558	12.4%						
		** multiple methods reported in some patients								
2.4.1	Proportion of time using sensors	<50%	126	16.3%	17.0%					
		50-75%	99	12.8%	13.4%					
		>75-100%	515	66.7%	69.6%					
		Missing	32	4.1%						
		Sum	772	100%	100%					
** of patients using cgm/flash										
2.4	Management method	Diet only	122	2.7%	2.8%					
		Metformin**	2423	54.0%	54.6%					
		Sulphonylurea**	679	15.1%	15.3%					
		Glitazone**	13	0.3%	0.3%					
		Acarbose**	16	0.4%	0.4%					
		DPP4 inhibitor**	807	18.0%	18.2%					
		SGLT2 inhibitor**	1045	23.3%	23.6%					
		GLP1 agonist**	722	16.1%	16.3%					
		Insulin**	3055	68.1%	68.9%					
		Missing	48	1.1%						
		** monotherapy or in combination with other treatments								
2.4.1	Insulin duration	<1 year	332	10.9%	11.5%					
		1-5 years	642	21.0%	22.2%					
		>5 years	1913	62.6%	66.3%					
		Missing	168	5.5%						
		Sum	3055	100%	100%					
2.4.2	Insulin mode	Basal**	547	12.2%	18.5%					
		Basal bolus**	1396	31.1%	47.1%					
		Pump**	373	8.3%	12.6%					
		Pre-mixed insulin*	782	17.4%	26.4%					
		Hybrid closed loop system*	45	1.0%	1.5%					
		Missing	29	0.6%						
		** multiple modes of insulin reported in some patients								

*Relative % = % of the total excluding the missing values

SECTION 3. HEIGHT, WEIGHT & SMOKING STATUS (ADULTS)

Item	Field	Category	Total	%	Relative %*	Median	Mean	SD	Min	Max
3.1	Weight	Weight (kg)	4230	94.3%	100%	87.0	90.2	23.8	0.0	240.0
		Missing	254	5.7%						
		Sum	4484	100%	100%					
3.2	Height	Height (m)	4174	93.1%	100%	1.7	1.7	0.1	0.0	2.1
		Missing	310	6.9%						
		Sum	4484	100%	100%					
3.3	Smoking status	Current	495	11.0%	11.4%					
		Past	1384	30.9%	31.9%					
		Never	2455	54.8%	56.6%					
		Missing	150	3.3%						
		Sum	4484	100%	100%					
3.3.1	Number of years spent smoking (current or past smokers)	<5 years	222	11.8%	12.6%					
		5-10 years	278	14.8%	15.8%					
		11-20 years	399	21.2%	22.7%					
		>20 years	856	45.6%	48.8%					
		Missing	124	6.6%						
		Sum	1879	100%	100%					

SECTION 4. BLOOD PRESSURE & ANTI-HYPERTENSIVE THERAPY (ADULTS)

Item	Field	Category	Total	%	Relative %*	Median	Mean	SD	Min	Max
4.1	Systolic blood pressure	Systolic (mmHg)	3866	86.2%	100%	130	132	17	50	215
		Missing	618	13.8%						
		Sum	4484	100%	100%					
4.1	Diastolic blood pressure	Diastolic (mmHg)	3859	86.1%	100%	77	76	11	33	130
		Missing	625	13.9%						
		Sum	4484	100%	100%					
4.2	Anti-hypertensive therapy	Yes	2666	59.5%	60.4%					
		No	1750	39.0%	39.6%					
		Missing	68	1.5%						
		Sum	4484	100%	100%					
4.2.1	Anti-hypertensive therapies (patients on anti-hypertensive therapy)	ACE inhibitor**	1197	26.7%	27.1%					
		Thiazide**	349	7.8%	7.9%					
		Calcium channel blocker**	831	18.5%	18.8%					
		Beta blocker*	805	18.0%	18.2%					
		ARB*	989	22.1%	22.4%					
		Other anti-hypertensive**	425	9.5%	9.6%					
		Missing	68	1.5%						

** multiple therapies reported in some patients

*Relative % = % of the total excluding the missing values

SECTION 5. DIABETES RELATED EYE DISEASE (ADULTS)

Item	Field	Category	Total	%	Relative %*	Median	Mean	SD	Min	Max
5.1	Attended	optometrist/ophthalmologist								
		Yes	3322	74.1%	76.1%					
		No	1041	23.2%	23.9%					
		Missing	121	2.7%						
		Sum	4484	100%	100%					
5.2	Fundus examination	Yes	3073	68.5%	69.9%					
		No	1321	29.5%	30.1%					
		Missing	90	2.0%						
		Sum	4484	100%	100%					
		5.3	Retinopathy	Yes	864	19.3%	19.7%			
No	3528			78.7%	80.3%					
Missing	92			2.1%						
Sum	4484			100%	100%					
5.4	Treatment for retinopathy			Yes	378	8.4%	8.8%			
		No	3921	87.4%	91.2%					
		Missing	185	4.1%						
		Sum	4484	100%	100%					
		5.5	Right or left cataract	Yes	812	18.1%	18.5%			
No	3576			79.8%	81.5%					
Missing	96			2.1%						
Sum	4484			100%	100%					

*Relative % = % of the total excluding the missing values

SECTION 6. DIABETES RELATED FOOT PROBLEMS (ADULTS)

Item	Field	Category	Total	%	Relative %*	Median	Mean	SD	Min	Max
6.1	Peripheral neuropathy - last 12 months	Yes	991	22.1%	22.3%					
		No	3448	76.9%	77.7%					
		Missing	45	1.0%						
		Sum	4484	100%	100%					
		Peripheral neuropathy - previous								
		Yes	796	17.8%	18.2%					
		No	3570	79.6%	81.8%					
		Missing	118	2.6%						
		Sum	4484	100%	100%					
		Foot ulceration - last 12 months								
6.2	Foot ulceration - last 12 months	Yes	257	5.7%	5.8%					
		No	4179	93.2%	94.2%					
		Missing	48	1.1%						
		Sum	4484	100%	100%					
		Foot ulceration - previous								
		Yes	259	5.8%	5.9%					
		No	4148	92.5%	94.1%					
		Missing	77	1.7%						
		Sum	4484	100%	100%					
		Peripheral vascular disease - last 12 months								
6.3	Peripheral vascular disease - last 12 months	Yes	336	7.5%	7.6%					
		No	4093	91.3%	92.4%					
		Missing	55	1.2%						
		Sum	4484	100%	100%					
		Peripheral vascular disease - previous								
		Yes	283	6.3%	6.5%					
		No	4074	90.9%	93.5%					
		Missing	127	2.8%						
		Sum	4484	100%	100%					
		Lower limb amputation - last 12 months								
6.4	Lower limb amputation - last 12 months	Yes	76	1.7%	1.7%					
		No	4286	95.6%	98.3%					
		Missing	122	2.7%						
		Sum	4484	100%	100%					
		Minor lower limb amputation - last 12 months								
		Yes	64	84.2%	84.2%					
		No	12	15.8%	15.8%					
		Missing	0	0.0%						
		Sum	76	100%	100%					
		Major lower limb amputation - last 12 months								
		Yes	9	11.8%	12.0%					
		No	66	86.8%	88.0%					
		Missing	1	1.3%						
		Sum	76	100%	100%					
		Lower limb amputation - previous								
		Yes	110	2.5%	2.9%					
		No	3648	81.4%	97.1%					
		Missing	726	16.2%						
		Sum	4484	100%	100%					
		Minor lower limb amputation - previous								
		Yes	82	74.5%	75.9%					
		No	26	23.6%	24.1%					
		Missing	2	1.8%						
		Sum	110	100%	100%					
		Major lower limb amputation - previous								
		Yes	23	20.9%	21.3%					
		No	85	77.3%	78.7%					
		Missing	2	1.8%						
		Sum	110	100%	100%					

*Relative % = % of the total excluding the missing values

SECTION 7. MEDICATIONS & LIPIDS (ADULTS)

Item	Field	Category	Total	%	Relative %*	Median	Mean	SD	Min	Max
7.1	Aspirin	Yes	1157	25.8%	25.9%					
		No	3290	73.4%	73.7%					
		Contraindicated	19	0.4%	0.4%					
		Missing	18	0.4%						
		Sum	4484	100%	100.0%					
7.2	Other anti-platelets	Yes	324	7.2%	7.3%					
		No	4118	91.8%	92.5%					
		Contraindicated	8	0.2%	0.2%					
		Missing	34	0.8%						
		Sum	4484	100%	100.0%					
7.3	Anti-coagulants	Yes	372	8.3%	8.4%					
		No	4073	90.8%	91.5%					
		Contraindicated	6	0.1%	0.1%					
		Missing	33	0.7%						
		Sum	4484	100%	100%					
7.4	Lipid lowering therapy	Yes	2748	61.3%	61.5%					
		No	1722	38.4%	38.5%					
		Missing	14	0.3%						
		Sum	4484	100%	100%					
7.4.1	Statin (of patients on lipid lowering therapy)	Yes	2544	92.6%	92.8%					
		No	167	6.1%	6.1%					
		Contraindicated	29	1.1%	1.1%					
		Missing	8	0.3%						
		Sum	2748	100%	100%					
7.4.2	Fibrate (of patients on lipid lowering therapy)	Yes	393	14.3%	14.7%					
		No	2282	83.0%	85.1%					
		Contraindicated	7	0.3%	0.3%					
		Missing	66	2.4%						
		Sum	2748	100%	100%					
7.4.3	Ezetimibe (of patients on lipid lowering therapy)	Yes	420	15.3%	15.7%					
		No	2245	81.7%	83.9%					
		Contraindicated	10	0.4%	0.4%					
		Missing	73	2.7%						
		Sum	2748	100%	100%					
7.4.4	Fish oil (of patients on lipid lowering therapy)	Yes	137	5.0%	5.1%					
		No	2534	92.2%	94.8%					
		Contraindicated	2	0.1%	0.1%					
		Missing	75	2.7%						
		Sum	2748	100%	100%					

*Relative % = % of the total excluding the missing values

SECTION 7. MEDICATIONS & LIPIDS (ADULTS) (continued)

Item	Field	Category	Total	%	Relative %*	Median	Mean	SD	Min	Max
7.5	Lipids measured									
		Yes	3099	69.1%	69.1%					
		No	1385	30.9%	30.9%					
		Missing	0	0.0%						
		Sum	4484	100%	100%					
7.5.1	Total cholesterol (of patients with lipids measured)									
		Total cholesterol (mmol/L)	3088	99.6%	100%	4.1	4.3	1.2	1.4	16.6
		Missing	11	0.4%						
		Sum	3099	100%	100%					
7.5.2	LDL (of patients with lipids measured)									
		LDL (mmol/L)	2662	85.9%	100%	2.0	2.2	1.0	0.0	7.9
		Missing	437	14.1%						
		Sum	3099	100%	100%					
7.5.3	HDL (of patients with lipids measured)									
		HDL (mmol/L)	2709	87.4%	100%	1.1	1.2	0.4	0.0	5.6
		Missing	390	12.6%						
		Sum	3099	100%	100%					
7.5.4	Triglycerides (of patients with lipids measured)									
		Triglycerides (mmol/L)	2995	96.6%	100%	1.6	2.0	1.9	0.3	36.9
		Missing	104	3.4%						
		Sum	3099	100%	100%					
7.5.5	Fasting lipids (of patients with lipids measured)									
		Yes	2424	78.2%	82.6%					
		No	512	16.5%	17.4%					
		Missing	163	5.3%						
		Sum	3099	100%	100%					

*Relative % = % of the total excluding the missing values

SECTION 8. COMPLICATIONS/EVENTS/COMORBIDITIES (ADULTS)

Item	Field	Category	Total	%	Relative %*	Median	Mean	SD	Min	Max
8.1	Stroke - last 12 months	Yes	60	1.3%	1.3%					
		No	4387	97.8%	98.7%					
		Missing	37	0.8%						
		Sum	4484	100%	100%					
		Stroke - previous								
		Yes	224	5.0%	5.1%					
		No	4148	92.5%	94.9%					
		Missing	112	2.5%						
		Sum	4484	100%	100%					
		Myocardial infarction - last 12 months								
8.2	Myocardial infarction - last 12 months	Yes	129	2.9%	2.9%					
		No	4311	96.1%	97.1%					
		Missing	44	1.0%						
		Sum	4484	100%	100%					
		Myocardial infarction - previous								
		Yes	446	9.9%	10.2%					
		No	3929	87.6%	89.8%					
		Missing	109	2.4%						
		Sum	4484	100%	100%					
		CABG/Angioplasty - last 12 months								
8.3	CABG/Angioplasty - last 12 months	Yes	121	2.7%	2.7%					
		No	4324	96.4%	97.3%					
		Missing	39	0.9%						
		Sum	4484	100%	100%					
		CABG/Angioplasty - previous								
		Yes	437	9.7%	10.0%					
		No	3940	87.9%	90.0%					
		Missing	107	2.4%						
		Sum	4484	100%	100%					
		Congestive cardiac failure - last 12 months								
8.4	Congestive cardiac failure - last 12 months	Yes	189	4.2%	4.4%					
		No	4127	92.0%	95.6%					
		Missing	168	3.7%						
		Sum	4484	100%	100%					
		Congestive cardiac failure - previous								
		Yes	210	4.7%	4.9%					
		No	4081	91.0%	95.1%					
		Missing	193	4.3%						
		Sum	4484	100%	100%					
		End stage kidney disease - last 12 months								
8.5	End stage kidney disease - last 12 months	Yes	187	4.2%	4.2%					
		No	4259	95.0%	95.8%					
		Missing	38	0.8%						
		Sum	4484	100%	100%					
		End stage kidney disease - previous								
		Yes	197	4.4%	4.5%					
		No	4175	93.1%	95.5%					
		Missing	112	2.5%						
		Sum	4484	100%	100%					
		Blindness - last 12 months								
8.6	Blindness - last 12 months	Yes	82	1.8%	1.9%					
		No	4311	96.1%	98.1%					
		Missing	91	2.0%						
		Sum	4484	100%	100%					
		Blindness - previous								
		Yes	72	1.6%	1.6%					
		No	4300	95.9%	98.4%					
		Missing	112	2.5%						
		Sum	4484	100%	100%					
		Sexual dysfunction - last 12 months								
8.7	Sexual dysfunction - last 12 months	Yes	524	11.7%	12.2%					
		No	3763	83.9%	87.8%					
		Missing	197	4.4%						
		Sum	4484	100%	100%					

*Relative % = % of the total excluding the missing values

SECTION 8. COMPLICATIONS/EVENTS/COMORBIDITIES (ADULTS) (continued)

Item	Field	Category	Total	%	Relative %*	Median	Mean	SD	Min	Max
		Sexual dysfunction - previous								
		Yes	524	11.7%	12.2%					
		No	3763	83.9%	87.8%					
		Missing	197	4.4%						
		Sum	4484	100%	100%					
8.8		Dementia - last 12 months								
		Yes	62	1.4%	1.4%					
		No	4247	94.7%	98.6%					
		Missing	175	3.9%						
		Sum	4484	100%	100%					
		Dementia - previous								
		Yes	36	0.8%	0.8%					
		No	4263	95.1%	99.2%					
		Missing	185	4.1%						
		Sum	4484	100%	100%					
8.9		Diabetic ketoacidosis - last 12 months								
		Yes	124	2.8%	2.9%					
		No	4193	93.5%	97.1%					
		Missing	167	3.7%						
		Sum	4484	100%	100%					
		Diabetic ketoacidosis - previous								
		Yes	354	7.9%	8.2%					
		No	3949	88.1%	91.8%					
		Missing	181	4.0%						
		Sum	4484	100%	100%					
8.10		Hyperosmolar hyperglycaemic state - last 12 months								
		Yes	35	0.8%	0.8%					
		No	4276	95.4%	99.2%					
		Missing	173	3.9%						
		Sum	4484	100%	100%					
		Hyperosmolar hyperglycaemic state - previous								
		Yes	40	0.9%	0.9%					
		No	4254	94.9%	99.1%					
		Missing	190	4.2%						
		Sum	4484	100%	100%					
8.11		Severe hypoglycaemia - last 12 months								
		Yes	199	4.4%	4.5%					
		No	4225	94.2%	95.5%					
		Missing	60	1.3%						
		Sum	4484	100%	100%					
8.11.1		Number of episodes (of patients with severe hypoglycaemia)								
		1-2 episodes	119	59.8%	64.3%					
		3-5 episodes	36	18.1%	19.5%					
		>5 episodes	30	15.1%	16.2%					
		Missing	14	7.0%						
		Sum	199	100%	100%					
		Severe hypoglycaemia - previous								
		Yes	386	8.6%	9.0%					
		No	3888	86.7%	91.0%					
		Missing	210	4.7%						
		Sum	4484	100%	100%					
8.12		Malignancy								
		Metastatic solid tumour**	90	2.0%	2.1%					
		Non-metastatic solid tumour**	173	3.9%	4.1%					
		Leukaemia**	21	0.5%	0.5%					
		Lymphoma**	15	0.3%	0.4%					
		Other**	107	2.4%	2.5%					
		Not applicable	3840	85.6%	90.6%					
		Missing	246	5.5%						
		** multiple malignancies reported in some patients								
8.13		Liver disease								
		Mild	381	8.5%	9.0%					
		Moderate/severe	115	2.6%	2.7%					
		Not applicable	3717	82.9%	88.2%					
		Missing	271	6.0%						
		Sum	4484	100%	100%					

SECTION 9. RENAL FUNCTION & BLOOD GLUCOSE CONTROL (ADULTS)

Item	Field	Category	Total	%	Relative %*	Median	IQR	Min	Max
9.1		Urinary protein/albumin result (all units)							
		Result	2612	58.3%	100%				
		Missing	1872	41.7%					
		Sum	4484	100%	100%				
		Urinary protein/albumin result (mg/L)							
		Result	906	20.2%	100%	10.0	4.0 - 39.0	0.0	5935.0
		Urinary protein/albumin result (µg/min)							
		Result	6	0.1%	100%	6.0	2.0 - 33.0	2.0	33.0
		Urinary protein/albumin result (mg/24hr)							
		Result	7	0.2%	100%	3.0	2.0 - 306.0	0.0	743.0
		Albumin:creatinine (ratio)							
		Result	1631	36.4%	100%	2.0	1.0 - 8.0	0.0	1210.0
9.2		Serum creatinine							
		Creatinine (µmol/L)	3822	85.2%	100%	74	63.0 - 87.0	0.0	1700.0
		Missing	662	14.8%					
		Sum	4484	100%	100%				

Item	Field	Category	Total	%	Relative %*	Median	Mean	SD	Min	Max
9.3		HbA_{1c} result								
		HbA _{1c} (%)	4262	95.0%	100%	7.9	8.3	1.7	2.2	17.9
		Missing	222	5.0%						
		Sum	4484	100%	100%					
9.3.1		HbA_{1c} (%) recorded								
		HbA _{1c} (%)	4179	95.0%	100%	7.9	8.3	1.7	4.2	17.9
		Missing	222	5.0%						
		Sum	4401	100%	100%					
9.3.2		HbA_{1c} (mmol/mol) recorded								
		HbA _{1c} (mmol/mol)	1922	89.6%	100%	64.0	67.4	19.9	0.0	172.0
		Missing	222	10.4%						
		Sum	2144	100%	100%					

*Relative % = % of the total excluding the missing values

4.2 Frequency Count Data (GDM)

SECTION 1. PATIENT DEMOGRAPHICS (GDM)										
Item	Field	Category	Total	%	Relative %*	Median	Mean	SD	Min	Max
1.1	Date of birth									
		DOB	163	100.0%	100%					
		Missing	0	0.0%						
		Sum	163	100%	100%					
1.2	Age									
		Age (years)	163	100.0%	100%	33.2	32.8	4.8	22.4	44.0
		Missing	0	0.0%						
		Sum	163	100%	100%					
1.3	Date of visit									
		Visit Date	163	100.0%	100%					
		Missing	0	0.0%						
		Sum	163	100%	100%					
1.4	Initial visit									
		Yes	59	36.2%	36.9%					
		No	101	62.0%	63.1%					
		Missing	3	1.8%						
		Sum	163	100%	100%					
1.5	Aboriginal/Torres Strait Islander									
		Yes	10	6.1%	6.2%					
		No	151	92.6%	93.8%					
		Missing	2	1.2%						
		Sum	163	100%	100%					
1.6	Country of birth									
		Country	160	98%	100%					
		Missing	3	1.8%						
		Sum	163	100%	100%					
1.7	NDSS member									
		Yes	123	75.5%	77.4%					
		No	36	22.1%	22.6%					
		Missing	4	2.5%						
		Sum	163	100%	100%					
1.8	DVA patient									
		Yes	1	0.6%	0.6%					
		No	159	97.5%	99.4%					
		Missing	3	1.8%						
		Sum	163	100%	100%					

*Relative % = % of the total excluding the missing values

SECTION 2. DIABETES TYPE & MANAGEMENT (GDM)

Item	Field	Category	Total	%	Relative %*	Median	Mean	SD	Min	Max
2.1	Year of diagnosis									
		Year	160	98.2%	100%					
		Missing	3	1.8%						
		Sum	163	100%	100%					
2.2	Duration of diabetes									
		Duration (years)	160	98.2%	100%	0.0	0.1	0.5	0.0	6.0
		Missing	3	1.8%						
		Sum	163	100%	100%					
2.3	Blood glucose monitoring									
		None	2	1.2%	1.2%					
		Finger pricking**	154	94.5%	95.1%					
		Continuous glucose monitoring**	0	0.0%	NA					
		Flash glucose monitoring**	0	0.0%	NA					
		Missing	0	0.0%						
		** multiple methods reported in some patients								
2.4	Management method									
		Diet only	71	43.6%	43.8%					
		Metformin**	15	9.2%	9.3%					
		Sulphonylurea**	0	0.0%	0.0%					
		Glitazone**	0	0.0%	0.0%					
		Acarbose**	0	0.0%	0.0%					
		DPP4 inhibitor**	0	0.0%	0.0%					
		SGLT2 inhibitor**	0	0.0%	0.0%					
		GLP1 agonist**	1	0.6%	0.6%					
		Insulin**	78	47.9%	48.1%					
		Missing	1	0.6%						
		** monotherapy or in combination with other treatments								
2.4.1	Insulin duration									
		<1 year	77	98.7%	100.0%					
		1-5 years	0	0.0%	0.0%					
		>5 years	0	0.0%	0.0%					
		Missing	1	1.3%						
		Sum	78	100%	100%					
2.4.2	Insulin mode									
		Basal**	57	35.0%	73.1%					
		Basal bolus**	21	12.9%	26.9%					
		Pump**	0	NA	0.0%					
		Pre-mixed insulin*	2	1.2%	2.6%					
		Hybrid closed loop system*	0	NA	0.0%					
		Missing	0	NA						
		** multiple modes of insulin reported in some patients								

*Relative % = % of the total excluding the missing values

SECTION 3. HEIGHT, WEIGHT & SMOKING STATUS (GDM)

Item	Field	Category	Total	%	Relative %*	Median	Mean	SD	Min	Max
3.1	Weight									
		Weight (kg)	150	92.0%	100%	83.0	86.8	20.3	52.7	140.4
		Missing	13	8.0%						
		Sum	163	100%	100%					
3.2	Height									
		Height (m)	142	87.1%	100%	1.6	1.6	0.1	1.5	1.9
		Missing	21	12.9%						
		Sum	163	100%	100%					
3.3	Smoking status									
		Current	14	8.6%	8.6%					
		Past	17	10.4%	10.5%					
		Never	131	80.4%	80.9%					
		Missing	1	0.6%						
		Sum	163	100%	100%					
3.3.1	Number of years spent smoking (current or past smokers)									
		<5 years	9	29.0%	31.0%					
		5-10 years	12	38.7%	41.4%					
		11-20 years	8	25.8%	27.6%					
		>20 years	0	0.0%	0.0%					
		Missing	2	6.5%						
		Sum	31	100%	100%					

SECTION 4. BLOOD PRESSURE & ANTI-HYPERTENSIVE THERAPY (GDM)

Item	Field	Category	Total	%	Relative %*	Median	Mean	SD	Min	Max
4.1	Systolic blood pressure									
		Systolic (mmHg)	134	82.2%	100%	115	115	11	90	160
		Missing	29	17.8%						
		Sum	163	100%	100%					
4.1	Diastolic blood pressure									
		Diastolic (mmHg)	134	82.2%	100%	70	71	9	50	93
		Missing	29	17.8%						
		Sum	163	100%	100%					
4.2	Anti-hypertensive treatment									
		Yes	5	3.1%	3.1%					
		No	157	96.3%	96.9%					
		Missing	1	0.6%						
		Sum	163	100%	100%					
4.2.1	Anti-hypertensive therapies (of patients on anti-hypertensive therapy)									
		ACE inhibitor**	0	NA	0.0%					
		Thiazide**	0	NA	0.0%					
		Calcium channel blocker**	1	0.6%	0.6%					
		Beta blocker*	2	1.2%	1.2%					
		ARB*	0	NA	0.0%					
		Other anti-hypertensive**	2	1.2%	1.2%					
		Missing	1	0.6%						

** multiple therapies reported in some patients

*Relative % = % of the total excluding the missing values

SECTION 5. DIABETES RELATED EYE DISEASE (GDM)

Item	Field	Category	Total	%	Relative %*	Median	Mean	SD	Min	Max
5.1	Attended optometrist/ophthalmologist									
		Yes	9	5.5%	5.6%					
		No	152	93.3%	94.4%					
		Missing	2	1.2%						
		Sum	163	100%	100%					
5.2	Fundus examination									
		Yes	6	3.7%	3.7%					
		No	155	95.1%	96.3%					
		Missing	2	1.2%						
		Sum	163	100%	100%					
5.3	Retinopathy									
		Yes	0	0.0%	0.0%					
		No	160	98.2%	100.0%					
		Missing	3	1.8%						
		Sum	163	100%	100%					
5.4	Treatment for retinopathy									
		Yes	0	0.0%	0.0%					
		No	160	98.2%	100.0%					
		Missing	3	1.8%						
		Sum	163	100%	100%					
5.5	Right or left cataract									
		Yes	0	0.0%	0.0%					
		No	160	98.2%	100.0%					
		Missing	3	1.8%						
		Sum	163	100%	100%					

*Relative % = % of the total excluding the missing values

SECTION 6. DIABETES RELATED FOOT PROBLEMS (GDM)

Item	Field	Category	Total	%	Relative %*	Median	Mean	SD	Min	Max
6.1	Peripheral neuropathy - last 12 months	Yes	1	0.6%	0.6%					
		No	161	98.8%	99.4%					
		Missing	1	0.6%						
		Sum	163	100%	100%					
Peripheral neuropathy - previous	Yes	0	0.0%	0.0%						
	No	162	99.4%	100.0%						
	Missing	1	0.6%							
	Sum	163	100%	100%						
6.2	Foot ulceration - last 12 months	Yes	0	0.0%	0.0%					
		No	162	99.4%	100.0%					
		Missing	1	0.6%						
		Sum	163	100%	100%					
Foot ulceration - previous	Yes	0	0.0%	0.0%						
	No	162	99.4%	100.0%						
	Missing	1	0.6%							
	Sum	163	100%	100%						
6.3	Peripheral vascular disease - last 12 months	Yes	0	0.0%	0.0%					
		No	162	99.4%	100.0%					
		Missing	1	0.6%						
		Sum	163	100%	100%					
Peripheral vascular disease - previous	Yes	0	0.0%	0.0%						
	No	161	98.8%	100.0%						
	Missing	2	1.2%							
	Sum	163	100%	100%						
6.4	Lower limb amputation - last 12 months	Yes	0	0.0%	0.0%					
		No	162	99.4%	100.0%					
		Missing	1	0.6%						
		Sum	163	100%	100%					
Lower limb amputation - previous	Yes	0	0.0%	0.0%						
	No	162	99.4%	100.0%						
	Missing	1	0.6%							
	Sum	163	100%	100%						

*Relative % = % of the total excluding the missing values

SECTION 7. MEDICATIONS & LIPIDS (GDM)

Item	Field	Category	Total	%	Relative %*	Median	Mean	SD	Min	Max
7.1	Aspirin	Yes	22	13.5%	13.8%					
		No	137	84.0%	85.6%					
		Contraindicated	1	0.6%	0.6%					
		Missing	3	1.8%						
		Sum	163	100%	100.0%					
7.2	Other anti-platelets	Yes	0	0.0%	0.0%					
		No	161	98.8%	100.0%					
		Contraindicated	0	0.0%	0.0%					
		Missing	2	1.2%						
		Sum	163	100%	100.0%					
7.3	Anti-coagulants	Yes	0	0.0%	0.0%					
		No	161	98.8%	100.0%					
		Contraindicated	0	0.0%	0.0%					
		Missing	2	1.2%						
		Sum	163	100%	100%					
7.4	Lipid lowering therapy	Yes	0	0.0%	0.0%					
		No	161	98.8%	100.0%					
		Missing	2	1.2%						
		Sum	163	100%	100%					
		7.5	Lipids measured	Yes	6	3.7%	3.7%			
No	157			96.3%	96.3%					
Missing	0			0.0%						
Sum	163			100%	100%					
7.5.1	Total cholesterol (of patients with lipids measured)			Total cholesterol (mmol/L)	6	100.0%	100%	5.1	5.2	0.9
		Missing	0	0.0%						
		Sum	6	100%	100%					
7.5.2	LDL (of patients with lipids measured)	LDL (mmol/L)	5	83.3%	100%	2.7	2.7	0.6	2.1	3.5
		Missing	1	16.7%						
		Sum	6	100%	100%					
7.5.3	HDL (of patients with lipids measured)	HDL (mmol/L)	5	83.3%	100%	1.6	2.0	1.3	1.1	4.3
		Missing	1	16.7%						
		Sum	6	100%	100%					
7.5.4	Triglycerides (of patients with lipids measured)	Triglycerides (mmol/L)	5	83.3%	100%	1.4	1.6	0.6	0.9	2.3
		Missing	1	16.7%						
		Sum	6	100%	100%					
7.5.5	Fasting lipids (of patients with lipids measured)	Yes	5	83.3%	83.3%					
		No	1	16.7%	16.7%					
		Missing	0	0.0%						
		Sum	6	100%	100%					

*Relative % = % of the total excluding the missing values

SECTION 8. COMPLICATIONS/EVENTS/COMORBIDITIES (GDM)

Item	Field	Category	Total	%	Relative %*	Median	Mean	SD	Min	Max
8.1	Stroke - last 12 months	Yes	0	0.0%	0.0%					
		No	162	99.4%	100.0%					
		Missing	1	0.6%						
		Sum	163	100%	100%					
Stroke - previous	Yes	0	0.0%	0.0%						
	No	162	99.4%	100.0%						
	Missing	1	0.6%							
	Sum	163	100%	100%						
8.2	Myocardial infarction - last 12 months	Yes	0	0.0%	0.0%					
		No	162	99.4%	100.0%					
		Missing	1	0.6%						
		Sum	163	100%	100%					
Myocardial infarction - previous	Yes	0	0.0%	0.0%						
	No	162	99.4%	100.0%						
	Missing	1	0.6%							
	Sum	163	100%	100%						
8.3	CABG/Angioplasty - last 12 months	Yes	0	0.0%	0.0%					
		No	162	99.4%	100.0%					
		Missing	1	0.6%						
		Sum	163	100%	100%					
CABG/Angioplasty - previous	Yes	0	0.0%	0.0%						
	No	162	99.4%	100.0%						
	Missing	1	0.6%							
	Sum	163	100%	100%						
8.4	Congestive cardiac failure - last 12 months	Yes	0	0.0%	0.0%					
		No	162	99.4%	100.0%					
		Missing	1	0.6%						
		Sum	163	100%	100%					
Congestive cardiac failure - previous	Yes	0	0.0%	0.0%						
	No	161	98.8%	100.0%						
	Missing	2	1.2%							
	Sum	163	100%	100%						
8.5	End stage kidney disease - last 12 months	Yes	0	0.0%	0.0%					
		No	162	99.4%	100.0%					
		Missing	1	0.6%						
		Sum	163	100%	100%					
End stage kidney disease - previous	Yes	0	0.0%	0.0%						
	No	161	98.8%	100.0%						
	Missing	2	1.2%							
	Sum	163	100%	100%						

*Relative % = % of the total excluding the missing values

SECTION 8. COMPLICATIONS/EVENTS/COMORBIDITIES (GDM) (continued)

Item	Field	Category	Total	%	Relative %*	Median	Mean	SD	Min	Max
8.6	Blindness - last 12 months	Yes	1	0.6%	0.6%					
		No	161	98.8%	99.4%					
		Missing	1	0.6%						
		Sum	163	100%	100%					
Blindness - previous	Yes	0	0.0%	0.0%						
	No	161	98.8%	100.0%						
	Missing	2	1.2%							
	Sum	163	100%	100%						
8.7	Sexual dysfunction - last 12 months	Yes	0	0.0%	0.0%					
		No	162	99.4%	100.0%					
		Missing	1	0.6%						
		Sum	163	100%	100%					
Sexual dysfunction - previous	Yes	0	0.0%	0.0%						
	No	162	99.4%	100.0%						
	Missing	1	0.6%							
	Sum	163	100%	100%						
8.8	Dementia - last 12 months	Yes	0	0.0%	0.0%					
		No	162	99.4%	100.0%					
		Missing	1	0.6%						
		Sum	163	100%	100%					
Dementia - previous	Yes	0	0.0%	0.0%						
	No	161	98.8%	100.0%						
	Missing	2	1.2%							
	Sum	163	100%	100%						
8.9	Diabetic ketoacidosis - last 12 months	Yes	0	0.0%	0.0%					
		No	162	99.4%	100.0%					
		Missing	1	0.6%						
		Sum	163	100%	100%					
Diabetic ketoacidosis - previous	Yes	0	0.0%	0.0%						
	No	161	98.8%	100.0%						
	Missing	2	1.2%							
	Sum	163	100%	100%						
8.10	Hyperosmolar hyperglycaemic state - last 12 months	Yes	0	0.0%	0.0%					
		No	162	99.4%	100.0%					
		Missing	1	0.6%						
		Sum	163	100%	100%					
Hyperosmolar hyperglycaemic state - previous	Yes	0	0.0%	0.0%						
	No	161	98.8%	100.0%						
	Missing	2	1.2%							
	Sum	163	100%	100%						

*Relative % = % of the total excluding the missing values

SECTION 8. COMPLICATIONS/EVENTS/COMORBIDITIES (GDM)

Item	Field	Category	Total	%	Relative %*	Median	Mean	SD	Min	Max
8.11		Severe hypoglycaemia - last 12 months								
		Yes	0	0.0%	0.0%					
		No	162	99.4%	100.0%					
		Missing	1	0.6%						
		Sum	163	100%	100%					
		Severe hypoglycaemia - previous								
		Yes	0	0.0%	0.0%					
		No	160	98.2%	100.0%					
		Missing	3	1.8%						
		Sum	163	100%	100%					
8.12		Malignancy								
		Metastatic solid tumour**	0	NA	0.0%					
		Non-metastatic solid tumour**	0	NA	0.0%					
		Leukaemia**	0	NA	0.0%					
		Lymphoma**	0	NA	0.0%					
		Other**	2	1.2%	1.3%					
		Not applicable	152	93.3%	98.7%					
		Missing	9	5.5%						
		** multiple malignancies reported in some patients								
8.13		Liver disease								
		Mild	3	1.8%	2.0%					
		Moderate/severe	0	0.0%	0.0%					
		Not applicable	149	91.4%	98.0%					
		Missing	11	6.7%						
		Sum	163	100%	100%					

*Relative % = % of the total excluding the missing values

SECTION 9. RENAL FUNCTION & BLOOD GLUCOSE CONTROL (GDM)

Item	Field	Category	Total	%	Relative %*	Median	IQR	Min	Max
9.1	Urinary protein/albumin result (all units)								
		Result	26	16.0%	100%				
		Missing	137	84.0%					
		Sum	163	100%	100%				
	Urinary protein/albumin result (mg/L)								
		Result	20	12.3%	100%	43.0	11.0 - 78.0	0.0	370.0
	Urinary protein/albumin result (µg/min)								
		Result	0	0.0%	NA	NA	NA	NA	NA
	Urinary protein/albumin result (mg/24hr)								
		Result	0	0.0%	NA	NA	NA	NA	NA
	Albumin:creatinine (ratio)								
		Result	7	4.3%	100%	7.0	2.0 - 10.0	1.0	21.0
9.2	Serum creatinine								
		Creatinine (µmol/L)	70	42.9%	100%	47	40 - 55	30	80
		Missing	93	57.1%					
		Sum	163	100%	100%				

Item	Field	Category	Total	%	Relative %*	Median	Mean	SD	Min	Max
9.3	HbA_{1c} result									
		HbA _{1c} (%)	48	29.4%	100%	5.3	5.3	0.4	4.4	6.5
		Missing	115	70.6%						
		Sum	163	100%	100%					
9.3.1	HbA_{1c} (%) recorded									
		HbA _{1c} (%)	48	29.4%	100%	5.3	5.3	0.4	4.4	6.5
		Missing	115	70.6%						
		Sum	163	100%	100%					
9.3.2	HbA_{1c} (mmol/mol) recorded									
		HbA _{1c} (mmol/mol)	42	25.8%	100%	34.0	34.1	4.3	24.0	48.0
		Missing	121	74.2%						
		Sum	163	100%	100%					

*Relative % = % of the total excluding the missing values

4.3 Frequency Count Data (Paediatrics)

SECTION 1. PATIENT DEMOGRAPHICS (PAEDIATRICS)

Item	Field	Category	Total	%	Relative %*	Median	Mean	SD	Min	Max
1.1	Date of birth									
		DOB	412	100.0%	100%					
		Missing	0	0.0%						
		Sum	412	100%	100%					
	Age									
		Age (years)	412	100.0%	100%	13.4	12.9	3.5	0.7	18.0
		Missing	0	0.0%						
		Sum	412	100%	100%					
1.2	Sex									
		Male	213	51.7%	51.7%					
		Female	199	48.3%	48.3%					
		Missing	0	0.0%						
		Sum	412	100%	100%					
1.2.1	Currently pregnant (females aged 12-<18 years)									
		Yes	1	0.7%	0.7%					
		No	147	98.7%	99.3%					
		Missing	1	0.7%						
		Sum	149	100%	100%					
1.3	Date of visit									
		Visit Date	412	100.0%	100%					
		Missing	0	0.0%						
		Sum	412	100%	100%					
1.4	Initial visit									
		Yes	19	4.6%	4.6%					
		No	391	94.9%	95.4%					
		Missing	2	0.5%						
		Sum	412	100%	100%					
1.5	Aboriginal/Torres Strait Islander									
		Yes	21	5.1%	5.1%					
		No	391	94.9%	94.9%					
		Missing	0	0.0%						
		Sum	412	100%	100%					
1.6	Country of birth									
		Country	412	100.0%	100%					
		Missing	0	0.0%						
		Sum	412	100%	100%					
1.7	NDSS member									
		Yes	411	99.8%	99.8%					
		No	1	0.2%	0.2%					
		Missing	0	0.0%						
		Sum	412	100%	100%					
1.8	DVA patient									
		Yes	0	0.0%	0.0%					
		No	412	100.0%	100.0%					
		Missing	0	0.0%						
		Sum	412	100%	100%					

*Relative % = % of the total excluding the missing values

SECTION 2. DIABETES TYPE & MANAGEMENT (PAEDIATRICS)

Item	Field	Category	Total	%	Relative %*	Median	Mean	SD	Min	Max
2.1	Year of diagnosis									
		Year	412	100.0%	100%					
		Missing	0	0.0%						
		Sum	412	100%	100%					
	Duration of diabetes									
		Duration (years)	412	100.0%	100%	3.0	4.4	3.7	0.0	16.0
		Missing	0	0.0%						
		Sum	412	100%	100%					
2.2	Type of diabetes									
		T1DM	384	93.2%	93.4%					
		T2DM	19	4.6%	4.6%					
		GDM	1	0.2%	0.2%					
		Don't know	0	0.0%	0.0%					
		Other	7	1.7%	1.7%					
		Missing	1	0.2%						
		Sum	412	100%	100%					
2.3	Blood glucose monitoring									
		None	24	5.8%	5.9%					
		Finger pricking**	78	18.9%	19.1%					
		Continuous glucose monitoring**	323	78.4%	79.2%					
		Flash glucose monitoring**	60	14.6%	14.7%					
		Missing	5	1.2%						
		** multiple methods reported in some patients								
2.4.1	Proportion of time using sensors									
		<50%	61	14.8%	16.9%					
		50-75%	50	12.1%	13.8%					
		>75-100%	251	60.9%	69.3%					
		Missing	50	12.1%						
		Sum	412	100%	100%					
		** of patients using cgm/flash								
2.4	Management method									
		Diet only	0	0.0%	0.0%					
		Metformin**	17	4.1%	4.2%					
		Sulphonylurea**	0	0.0%	0.0%					
		Glitazone**	0	0.0%	0.0%					
		Acarbose**	0	0.0%	0.0%					
		DPP4 inhibitor**	0	0.0%	0.0%					
		SGLT2 inhibitor**	1	0.2%	0.2%					
		GLP1 agonist**	2	0.5%	0.5%					
		Insulin**	392	95.1%	96.1%					
		Missing	4	1.0%						
		** monotherapy or in combination with other treatments								
2.4.1	Insulin duration									
		<1 year	79	20.2%	20.5%					
		1-5 years	182	46.4%	47.2%					
		>5 years	125	31.9%	32.4%					
		Missing	6	1.5%						
		Sum	392	100%	100%					
2.4.2	Insulin mode									
		Basal**	191	46.4%	49.5%					
		Basal bolus**	203	49.3%	52.6%					
		Pump**	182	44.2%	47.2%					
		Pre-mixed insulin*	3	0.7%	0.8%					
		Hybrid closed loop system*	14	3.4%	3.6%					
		Missing	3	0.7%						
		** multiple modes of insulin reported in some patients								

*Relative % = % of the total excluding the missing values

SECTION 3. HEIGHT, WEIGHT & SMOKING STATUS (PAEDIATRICS)

Item	Field	Category	Total	%	Relative %*	Median	Mean	SD	Min	Max
3.1	Weight									
		Weight (kg)	393	95.4%	100%	54.7	55.9	22.4	14.2	240.0
		Missing	19	4.6%						
		Sum	412	100%	100%					
3.2	Height									
		Height (m)	388	94.2%	100%	1.6	1.6	0.2	0.4	2.1
		Missing	24	5.8%						
		Sum	412	100%	100%					
3.3	Smoking status									
		Current	1	0.2%	0.2%					
		Past	2	0.5%	0.5%					
		Never	409	99.3%	99.3%					
		Missing	0	0.0%						
		Sum	412	100%	100%					
3.3.1	Number of years spent smoking (current or past smokers)									
		<5 years	2	66.7%	66.7%					
		5-10 years	1	33.3%	33.3%					
		11-20 years	0	0.0%	0.0%					
		>20 years	0	0.0%	0.0%					
		Missing	0	0.0%						
		Sum	3	100%	100%					

SECTION 4. BLOOD PRESSURE & ANTI-HYPERTENSIVE THERAPY (PAEDIATRICS)

Item	Field	Category	Total	%	Relative %*	Median	Mean	SD	Min	Max
4.1	Systolic blood pressure									
		Systolic (mmHg)	142	34.5%	100%	0	113	14	0	215
		Missing	270	65.5%						
		Sum	412	100%	100%					
4.1	Diastolic blood pressure									
		Diastolic (mmHg)	142	34.5%	100%	70	70	9	39	130
		Missing	270	65.5%						
		Sum	412	100%	100%					
4.2	Anti-hypertensive therapy									
		Yes	2	0.5%	0.5%					
		No	409	99.3%	99.5%					
		Missing	1	0.2%						
		Sum	412	100%	100%					
4.2.1	Anti-hypertensive therapies (patients on anti-hypertensive therapy)									
		ACE inhibitor**	2	0.5%	0.5%					
		Thiazide**	0	NA	0.0%					
		Calcium channel blocker**	0	NA	0.0%					
		Beta blocker*	0	NA	0.0%					
		ARB*	0	NA	0.0%					
		Other anti-hypertensive**	0	NA	0.0%					
		Missing	1	0.2%						

** multiple therapies reported in some patients

*Relative % = % of the total excluding the missing values

SECTION 5. DIABETES RELATED EYE DISEASE (PAEDIATRICS)

Item	Field	Category	Total	%	Relative %*	Median	Mean	SD	Min	Max
5.1	Attended	optometrist/ophthalmologist								
		Yes	21	5.1%	5.1%					
		No	389	94.4%	94.9%					
		Missing	2	0.5%						
		Sum	412	100%	100%					
5.2	Fundus examination									
		Yes	15	3.6%	3.7%					
		No	393	95.4%	96.3%					
		Missing	4	1.0%						
		Sum	412	100%	100%					
5.3	Retinopathy									
		Yes	1	0.2%	0.2%					
		No	407	98.8%	99.8%					
		Missing	4	1.0%						
		Sum	412	100%	100%					
5.4	Treatment for retinopathy									
		Yes	0	0.0%	0.0%					
		No	409	99.3%	100.0%					
		Missing	3	0.7%						
		Sum	412	100%	100%					
5.5	Right or left cataract									
		Yes	0	0.0%	0.0%					
		No	409	99.3%	100.0%					
		Missing	3	0.7%						
		Sum	412	100%	100%					

*Relative % = % of the total excluding the missing values

SECTION 6. DIABETES RELATED FOOT PROBLEMS (PAEDIATRICS)

Item	Field	Category	Total	%	Relative %*	Median	Mean	SD	Min	Max
6.1	Peripheral neuropathy - last 12 months	Yes	1	0.2%	0.2%					
		No	410	99.5%	99.8%					
		Missing	1	0.2%						
		Sum	412	100%	100%					
6.1	Peripheral neuropathy - previous	Yes	0	0.0%	0.0%					
		No	405	98.3%	100.0%					
		Missing	7	1.7%						
		Sum	412	100%	100%					
6.2	Foot ulceration - last 12 months	Yes	0	0.0%	0.0%					
		No	411	99.8%	100.0%					
		Missing	1	0.2%						
		Sum	412	100%	100%					
6.2	Foot ulceration - previous	Yes	0	0.0%	0.0%					
		No	405	98.3%	100.0%					
		Missing	7	1.7%						
		Sum	412	100%	100%					
6.3	Peripheral vascular disease - last 12 months	Yes	0	0.0%	0.0%					
		No	411	99.8%	100.0%					
		Missing	1	0.2%						
		Sum	412	100%	100%					
6.3	Peripheral vascular disease - previous	Yes	0	0.0%	0.0%					
		No	405	98.3%	100.0%					
		Missing	7	1.7%						
		Sum	412	100%	100%					
6.4	Lower limb amputation - last 12 months	Yes	0	0.0%	0.0%					
		No	40	9.7%	100.0%					
		Missing	372	90.3%						
		Sum	412	100%	100%					

*Relative % = % of the total excluding the missing values

SECTION 7. MEDICATIONS & LIPIDS (PAEDIATRICS)

Item	Field	Category	Total	%	Relative %*	Median	Mean	SD	Min	Max
7.1	Aspirin									
		Yes	0	0.0%	0.0%					
		No	411	99.8%	100.0%					
		Contraindicated	0	0.0%	0.0%					
		Missing	1	0.2%						
		Sum	412	100%	100.0%					
7.2	Other anti-platelets									
		Yes	0	0.0%	0.0%					
		No	411	99.8%	100.0%					
		Contraindicated	0	0.0%	0.0%					
		Missing	1	0.2%						
		Sum	412	100%	100.0%					
7.3	Anti-coagulants									
		Yes	0	0.0%	0.0%					
		No	410	99.5%	100.0%					
		Contraindicated	0	0.0%	0.0%					
		Missing	2	0.5%						
		Sum	412	100%	100%					
7.4	Lipid lowering therapy									
		Yes	1	0.2%	0.2%					
		No	410	99.5%	99.8%					
		Missing	1	0.2%						
		Sum	412	100%	100%					
7.4.1	Statin (of patients on lipid lowering therapy)									
		Yes	1	100.0%	100.0%					
		No	0	0.0%	0.0%					
		Contraindicated	0	0.0%	0.0%					
		Missing	0	0.0%						
		Sum	1	100%	100%					
7.4.2	Fibrate (of patients on lipid lowering therapy)									
		Yes	0	0.0%	0.0%					
		No	1	100.0%	100.0%					
		Contraindicated	0	0.0%	0.0%					
		Missing	0	0.0%						
		Sum	1	100%	100%					
7.4.3	Ezetimibe (of patients on lipid lowering therapy)									
		Yes	0	0.0%	0.0%					
		No	1	100.0%	100.0%					
		Contraindicated	0	0.0%	0.0%					
		Missing	0	0.0%						
		Sum	1	100%	100%					
7.4.4	Fish oil (of patients on lipid lowering therapy)									
		Yes	0	0.0%	0.0%					
		No	1	100.0%	100.0%					
		Contraindicated	0	0.0%	0.0%					
		Missing	0	0.0%						
		Sum	1	100%	100%					

*Relative % = % of the total excluding the missing values

SECTION 7. MEDICATIONS & LIPIDS (PAEDIATRICS) (continued)

Item	Field	Category	Total	%	Relative %*	Median	Mean	SD	Min	Max
7.5	Lipids measured									
		Yes	120	29.1%	29.1%					
		No	292	70.9%	70.9%					
		Missing	0	0.0%						
		Sum	412	100%	100%					
7.5.1	Total cholesterol (of patients with lipids measured)									
		Total cholesterol (mmol/L)	120	100.0%	100%	4.3	4.3	0.9	2.0	7.4
		Missing	0	0.0%						
		Sum	120	100%	100%					
7.5.2	LDL (of patients with lipids measured)									
		LDL (mmol/L)	89	74.2%	100%	2.4	2.4	0.7	0.8	4.8
		Missing	31	25.8%						
		Sum	120	100%	100%					
7.5.3	HDL (of patients with lipids measured)									
		HDL (mmol/L)	91	75.8%	100%	1.4	1.4	0.4	0.7	2.8
		Missing	29	24.2%						
		Sum	120	100%	100%					
7.5.4	Triglycerides (of patients with lipids measured)									
		Triglycerides (mmol/L)	117	97.5%	100%	0.9	1.2	0.9	0.3	6.0
		Missing	3	2.5%						
		Sum	120	100%	100%					
7.5.5	Fasting lipids (of patients with lipids measured)									
		Yes	33	27.5%	27.7%					
		No	86	71.7%	72.3%					
		Missing	1	0.8%						
		Sum	120	100%	100%					

*Relative % = % of the total excluding the missing values

SECTION 8. COMPLICATIONS/EVENTS/COMORBIDITIES (PAEDIATRICS)

Item	Field	Category	Total	%	Relative %*	Median	Mean	SD	Min	Max
8.1	Stroke - last 12 months	Yes	0	0.0%	0.0%					
		No	409	99.3%	100.0%					
		Missing	3	0.7%						
		Sum	412	100%	100%					
Stroke - previous	Yes	0	0.0%	0.0%						
	No	408	99.0%	100.0%						
	Missing	4	1.0%							
	Sum	412	100%	100%						
8.2	Myocardial infarction - last 12 months	Yes	0	0.0%	0.0%					
		No	409	99.3%	100.0%					
		Missing	3	0.7%						
		Sum	412	100%	100%					
Myocardial infarction - previous	Yes	0	0.0%	0.0%						
	No	408	99.0%	100.0%						
	Missing	4	1.0%							
	Sum	412	100%	100%						
8.3	CABG/Angioplasty - last 12 months	Yes	0	0.0%	0.0%					
		No	409	99.3%	100.0%					
		Missing	3	0.7%						
		Sum	412	100%	100%					
CABG/Angioplasty - previous	Yes	0	0.0%	0.0%						
	No	408	99.0%	100.0%						
	Missing	4	1.0%							
	Sum	412	100%	100%						
8.4	Congestive cardiac failure - last 12 months	Yes	0	0.0%	0.0%					
		No	409	99.3%	100.0%					
		Missing	3	0.7%						
		Sum	412	100%	100%					
Congestive cardiac failure - previous	Yes	0	0.0%	0.0%						
	No	408	99.0%	100.0%						
	Missing	4	1.0%							
	Sum	412	100%	100%						
8.5	End stage kidney disease - last 12 months	Yes	0	0.0%	0.0%					
		No	409	99.3%	100.0%					
		Missing	3	0.7%						
		Sum	412	100%	100%					
End stage kidney disease - previous	Yes	0	0.0%	0.0%						
	No	408	99.0%	100.0%						
	Missing	4	1.0%							
	Sum	412	100%	100%						
8.6	Blindness - last 12 months	Yes	0	0.0%	0.0%					
		No	409	99.3%	100.0%					
		Missing	3	0.7%						
		Sum	412	100%	100%					
Blindness - previous	Yes	0	0.0%	0.0%						
	No	408	99.0%	100.0%						
	Missing	4	1.0%							
	Sum	412	100%	100%						
8.7	Sexual dysfunction - last 12 months	Yes	0	0.0%	0.0%					
		No	409	99.3%	100.0%					
		Missing	3	0.7%						
		Sum	412	100%	100%					

*Relative % = % of the total excluding the missing values

SECTION 8. COMPLICATIONS/EVENTS/COMORBIDITIES (PAEDIATRICS) (continued)

Item	Field	Category	Total	%	Relative %*	Median	Mean	SD	Min	Max
		Sexual dysfunction - previous								
		Yes	0	0.0%	0.0%					
		No	409	99.3%	100.0%					
		Missing	3	0.7%						
		Sum	412	100%	100%					
8.8		Dementia - last 12 months								
		Yes	0	0.0%	0.0%					
		No	409	99.3%	100.0%					
		Missing	3	0.7%						
		Sum	412	100%	100%					
		Dementia - previous								
		Yes	0	0.0%	0.0%					
		No	408	99.0%	100.0%					
		Missing	4	1.0%						
		Sum	412	100%	100%					
8.9		Diabetic ketoacidosis - last 12 months								
		Yes	15	3.6%	3.7%					
		No	394	95.6%	96.3%					
		Missing	3	0.7%						
		Sum	412	100%	100%					
		Diabetic ketoacidosis - previous								
		Yes	33	8.0%	8.1%					
		No	374	90.8%	91.9%					
		Missing	5	1.2%						
		Sum	412	100%	100%					
8.10		Hyperosmolar hyperglycaemic state - last 12 months								
		Yes	0	0.0%	0.0%					
		No	407	98.8%	100.0%					
		Missing	5	1.2%						
		Sum	412	100%	100%					
		Hyperosmolar hyperglycaemic state - previous								
		Yes	1	0.2%	0.2%					
		No	404	98.1%	99.8%					
		Missing	7	1.7%						
		Sum	412	100%	100%					
8.11		Severe hypoglycaemia - last 12 months								
		Yes	16	3.9%	3.9%					
		No	391	94.9%	96.1%					
		Missing	5	1.2%						
		Sum	412	100%	100%					
8.11.1		Number of episodes (of patients with severe hypoglycaemia)								
		1-2 episodes	13	81.3%	86.7%					
		3-5 episodes	1	6.3%	6.7%					
		>5 episodes	1	6.3%	6.7%					
		Missing	1	6.3%						
		Sum	16	100%	100%					
		Severe hypoglycaemia - previous								
		Yes	86	20.9%	21.2%					
		No	319	77.4%	78.8%					
		Missing	7	1.7%						
		Sum	412	100%	100%					
8.12		Malignancy								
		Metastatic solid tumour**	0	NA	0.0%					
		Non-metastatic solid tumour**	0	NA	0.0%					
		Leukaemia**	0	NA	0.0%					
		Lymphoma**	0	NA	0.0%					
		Other**	0	NA	0.0%					
		Not applicable	409	99.3%	100.0%					
		Missing	3	0.7%						
		** multiple malignancies reported in some patients								
8.13		Liver disease								
		Mild	0	0.0%	0.0%					
		Moderate/severe	0	0.0%	0.0%					
		Not applicable	404	98.1%	100.0%					
		Missing	8	1.9%						
		Sum	412	100%	100%					

SECTION 9. RENAL FUNCTION & BLOOD GLUCOSE CONTROL (PAEDIATRICS)

Item	Field	Category	Total	%	Relative %*	Median	IQR	Min	Max
9.1	Urinary protein/albumin result (all units)								
		Result	81	19.7%	100%				
		Missing	331	80.3%					
		Sum	412	100%	100%				
	Urinary protein/albumin result (mg/L)								
		Result	13	3.2%	100%	4.0	3.0 - 5.0	0.0	87.0
	Urinary protein/albumin result (µg/min)								
		Result	1	0.2%	100%	6.0	6.0 - 6.0	6.0	6.0
	Urinary protein/albumin result (mg/24hr)								
		Result	0	0.0%	NA	NA	NA	NA	NA
	Albumin:creatinine (ratio)								
		Result	67	16.3%	100%	1.0	1.0 - 2.0	0.0	10.0
9.2	Serum creatinine								
		Creatinine (µmol/L)	21	5.1%	100%	65.0	49.8 - 71.5	41.0	98.0
		Missing	391	94.9%					
		Sum	412	100%	100%				

Item	Field	Category	Total	%	Relative %*	Median	Mean	SD	Min	Max
9.3	HbA_{1c} result									
		HbA _{1c} (%)	407	98.8%	100%	7.7	7.7	2.2	2.2	14.1
		Missing	5	1.2%						
	Sum	412	100%	100%						
9.3.1	HbA_{1c} (%) recorded									
		HbA _{1c} (%)	377	98.7%	100%	7.9	8.2	1.6	4.2	17.9
		Missing	5	1.3%						
	Sum	382	100%	100%						
9.3.2	HbA_{1c} (mmol/mol) recorded									
		HbA _{1c} (mmol/mol)	382	98.7%	100%	61.0	59.7	24.3	0.0	172.0
		Missing	5	1.3%						
	Sum	387	100%	100%						

*Relative % = % of the total excluding the missing values

5.1 Missing Data (Adults)

Table 5.1.1 Overall missing data (Adults)

	0 and ≤5	>5 and ≤10	>10 and ≤15	>15 and ≤20	>20 and ≤40	>40
Missing data	80.0%	12.5%	5.0%	1.3%	0.0%	1.3%

Table 5.1.2 Missing data by field (Adults)

Item no.	Clinical Parameters	2021 (n=4484)		2019 (n=6436)	
		n	%	n	%
Demographics					
1.1	Date of birth	0	0.0	0	0.0
1.2	Gender	49	1.1	77	1.3
1.2.1	Currently pregnant (females aged 18-55 yrs)	17	0.4	78	1.3
1.3	Date of visit	0	0.0	0	0.0
1.4	Initial visit	124	2.8	82	1.3
1.5	Aboriginal/Torres Strait Islander	86	1.9	394	6.4
1.6	Country of birth	89	2.0	277	4.5
1.7	NDSS	190	4.2	612	10.0
1.8	DVA	157	3.5	605	9.9
Diabetes type and management					
2.1	Year of diagnosis	126	2.8	127	2.1
2.2	Type of diabetes	19	0.4	26	0.4
2.3	Blood glucose monitoring	5	0.1	558	9.1
2.4	Management method	48	1.1	55	0.9
2.4.1	Years on insulin	302	6.8	301	4.9
2.4.2	Insulin mode	29	0.6	63	1.0
Height, weight and smoking status					
3.1	Weight	254	5.7	193	3.2
3.2	Height	310	6.9	504	8.2
3.3	Smoking status	150	3.3	293	4.8
3.3.1	Number of years spent smoking (current or past smokers)	124	6.6	176	6.9
Blood pressure					
4.1	Blood pressure - systolic	618	13.8	219	3.6
4.1	Blood pressure - diastolic	625	13.9	219	3.6
4.2	On anti-hypertensive treatment	68	1.5	34	0.6
Diabetes related eye disease					
5.1	Attended optometrist/ophthalmologist	121	2.0	36	0.8
5.2	Fundus examination	90	2.0	50	0.8
5.3	Retinopathy	92	2.1	75	1.2
5.4	Treatment for retinopathy	185	4.1	88	1.4
5.5	Right or left cataract	96	2.1	91	1.5
Diabetes related foot problems					
6.1	Peripheral neuropathy - last 12 months	45	1.0	33	0.5
	Peripheral neuropathy - previous	118	2.6	171	2.8
6.2	Foot ulceration - last 12 months	48	1.1	28	0.5
	Foot ulceration - previous	77	1.7	78	1.3
6.3	Peripheral vascular disease - last 12 months	55	1.2	32	0.5
	Peripheral vascular disease - previous	127	2.8	173	2.8
6.4	Lower limb amputation - last 12 months	122	2.7	31	0.5
	Lower limb amputation - previous	726	16.2	170	2.8
Medications and lipids					
7.1	Aspirin	18	0.4	14	0.2
7.2	Other anti-platelets	34	0.8	21	0.3
7.3	Anti-coagulants	33	0.7	22	0.4
7.4	On lipid lowering therapy	14	0.3	16	0.3
7.4.1	On lipid lowering therapy - Statin	8	0.2	5	0.1
7.4.2	On lipid lowering therapy - Fibrate	66	1.5	55	0.9
7.4.3	On lipid lowering therapy - Ezetimibe	73	1.6	58	0.9
7.4.4	On lipid lowering therapy - Fish oil	75	1.7	63	1.0

Item no.	Clinical Parameters	n	%	n	%
7.5	Lipids measured	0	0.0	16	0.3
7.5.1	Lipids measured - Total cholesterol	11	0.2	48	0.8
7.5.2	Lipids measured - LDL cholesterol	437	9.7	674	11.0
7.5.3	Lipids measured - HDL cholesterol	390	8.7	563	9.2
7.5.4	Lipids measured - Triglycerides	104	2.3	173	2.8
7.5.5	Lipids measured - Fasting lipids	163	3.6	19	0.3
Complications/events/comorbidities					
8.1	Stroke - last 12 months	37	0.8	14	0.2
	Stroke - previous	112	2.5	166	2.7
8.2	Myocardial infarction - last 12 months	44	1.0	17	0.3
	Myocardial infarction - previous	109	2.4	159	2.6
8.3	CABG - last 12 months	39	0.9	20	0.3
	CABG - previous	107	2.4	159	2.6
8.4	Congestive cardiac failure - last 12 months	168	3.7	493	8.1
	Congestive cardiac failure - previous	193	4.3	550	9.0
8.5	End stage renal disease - last 12 months	38	0.8	12	0.2
	End stage renal disease - previous	112	2.5	162	2.6
8.6	Blindness - last 12 months	91	2.0	106	1.7
	Blindness - previous	112	2.5	164	2.7
8.7	Sexual dysfunction - last 12 months	197	4.4	128	2.1
	Sexual dysfunction - previous	255	5.7	233	7.3
8.8	Dementia - last 12 months	175	3.9	493	8.1
	Dementia - previous	185	4.1	550	9.0
8.9	Diabetic ketoacidosis - last 12 months	167	3.7	105	1.7
	Diabetic ketoacidosis - previous	181	4.0	171	2.8
8.10	Hyperosmolar hyperglycaemic state - last 12 months	173	3.9	109	1.8
	Hyperosmolar hyperglycaemic state - previous	190	4.2	174	2.8
8.11	Severe hypoglycaemia - last 12 months	60	1.3	125	2.0
	Severe hypoglycaemia - last 12 months - No. of episodes	14	7.0	5	1.4
	Severe hypoglycaemia - previous	210	4.7	567	9.3
8.12	Malignancy	246	5.5	489	8.0
8.13	Liver disease	271	6.0	591	9.7
Renal function and blood glucose control					
9.1	Urinary protein/albumin collected	57	1.3	23	0.4
9.1.1	Urinary protein/albumin result	0	0.0	0	0.0
9.1.2	Urinary protein/albumin unit	61	1.4	0	0.0
9.2	Serum creatinine	662	14.8	931	15.2
9.3.1	Glycated haemoglobin reported (%)	305	6.8	416	6.8
9.3.2	Glycated haemoglobin reported (mmol/mol)	2562	57.1	971	15.9

5.2 Missing Data (GDM)

Table 5.2.1 Overall missing data (GDM)

	0 and ≤5	>5 and ≤10	>10 and ≤15	>15 and ≤20	>20 and ≤40	>40
Missing data	86.3%	5.0%	1.3%	2.5%	0.0%	3.8%

Table 5.2.2 Missing data by field (GDM)

Item no.	Clinical Parameters	2021 (n=163)		2019 (n=320)	
		n	%	n	%
Demographics					
1.1	Date of birth	0	0.0	0	0.0
1.2	Gender	0	0.0	0	0.0
1.2.1	Currently pregnant (females aged 18-55 yrs)	0	0.0	0	0.0
1.3	Date of visit	0	0.0	0	0.0
1.4	Initial visit	3	1.8	0	0.0
1.5	Aboriginal/Torres Strait Islander	2	1.2	1	0.3
1.6	Country of birth	3	1.8	3	0.9
1.7	NDSS	4	2.5	2	0.6
1.8	DVA	3	1.8	3	0.9
Diabetes type and management					
2.1	Year of diagnosis	1	0.6	1	0.3
2.2	Type of diabetes	0	0.0	0	0.0
2.3	Blood glucose monitoring	0	0.0	0	0.0
2.4	Management method	1	0.6	55	17.2
2.4.1	Years on insulin	20	0.4	63	19.6
2.4.2	Insulin mode	0	0.0	3	0.9
Height, weight and smoking status					
3.1	Weight	13	8.0	12	3.8
3.2	Height	21	12.9	20	6.3
3.3	Smoking status	1	0.6	6	1.9
3.3.1	Number of years spent smoking (current or past smokers)	2	6.5	0	0.0
Blood pressure					
4.1	Blood pressure - systolic	29	17.8	17	5.3
4.1	Blood pressure - diastolic	29	17.8	17	5.3
4.2	On anti-hypertensive treatment	1	0.6	0	0.0
Diabetes related eye disease					
5.1	Attended optometrist/ophthalmologist	2	1.2	36	0.0
5.2	Fundus examination	2	1.2	0	0.0
5.3	Retinopathy	3	1.8	1	0.3
5.4	Treatment for retinopathy	3	1.8	88	27.5
5.5	Right or left cataract	3	1.8	91	28.4
Diabetes related foot problems					
6.1	Peripheral neuropathy - last 12 months	1	0.6	0	0.0
	Peripheral neuropathy - previous	1	0.6	0	0.0
6.2	Foot ulceration - last 12 months	1	0.6	0	0.0
	Foot ulceration - previous	1	0.6	0	0.0
6.3	Peripheral vascular disease - last 12 months	1	0.6	0	0.0
	Peripheral vascular disease - previous	2	1.2	0	0.0
6.4	Lower limb amputation - last 12 months	1	0.6	0	0.0
	Lower limb amputation - previous	1	0.6	0	0.0
Medications and lipids					
7.1	Aspirin	3	1.8	0	0.0
7.2	Other anti-platelets	2	1.2	0	0.0
7.3	Anti-coagulants	2	1.2	0	0.0
7.4	On lipid lowering therapy	2	1.2	0	0.0
7.4.1	On lipid lowering therapy - Statin	0	0.0	0	0.0
7.4.2	On lipid lowering therapy - Fibrate	0	0.0	0	0.0
7.4.3	On lipid lowering therapy - Ezetimibe	0	0.0	0	0.0
7.4.4	On lipid lowering therapy - Fish oil	0	0.0	0	0.0

Item no.	Clinical Parameters	n	%	n	%
7.5	Lipids measured	0	0.0	1	0.3
7.5.1	Lipids measured - Total cholesterol	0	0.0	0	0.0
7.5.2	Lipids measured - LDL cholesterol	1	0.6	1	0.3
7.5.3	Lipids measured - HDL cholesterol	1	0.6	1	0.3
7.5.4	Lipids measured - Triglycerides	1	0.6	1	0.3
7.5.5	Lipids measured - Fasting lipids	0	0.0	0	0.0
Complications/events/comorbidities					
8.1	Stroke - last 12 months	1	0.6	0	0.0
	Stroke - previous	1	0.6	2	0.6
8.2	Myocardial infarction - last 12 months	1	0.6	0	0.0
	Myocardial infarction - previous	1	0.6	1	0.3
8.3	CABG - last 12 months	1	0.6	0	0.0
	CABG - previous	1	0.6	2	0.6
8.4	Congestive cardiac failure - last 12 months	1	0.6	0	0.0
	Congestive cardiac failure - previous	2	1.2	2	0.6
8.5	End stage renal disease - last 12 months	1	0.6	0	0.0
	End stage renal disease - previous	2	1.2	1	0.3
8.6	Blindness - last 12 months	1	0.6	0	0.0
	Blindness - previous	2	1.2	1	0.3
8.7	Sexual dysfunction - last 12 months	1	0.6	128	40.0
	Sexual dysfunction - previous	2	1.2	233	0.3
8.8	Dementia - last 12 months	1	0.6	0	0.0
	Dementia - previous	2	1.2	1	0.3
8.9	Diabetic ketoacidosis - last 12 months	1	0.6	0	0.0
	Diabetic ketoacidosis - previous	2	1.2	171	53.4
8.10	Hyperosmolar hyperglycaemic state - last 12 months	1	0.6	109	34.1
	Hyperosmolar hyperglycaemic state - previous	2	1.2	174	54.4
8.11	Severe hypoglycaemia - last 12 months	1	0.6	1	0.3
	Severe hypoglycaemia - last 12 months - No. of episodes	0	0.0	0	0.0
	Severe hypoglycaemia - previous	3	1.8	3	0.9
8.12	Malignancy	9	5.5	489	152.8
8.13	Liver disease	11	6.7	1	0.3
Renal function and blood glucose control					
9.1	Urinary protein/albumin collected	1	0.6	1	0.3
9.1.1	Urinary protein/albumin result	0	0.0	0	0.0
9.1.2	Urinary protein/albumin unit	0	0.0	0	0.0
9.2	Serum creatinine	93	57.1	241	75.3
9.3.1	Glycated haemoglobin reported (%)	115	70.6	228	71.3
9.3.2	Glycated haemoglobin reported (mmol/mol)	121	74.2	239	74.7

5.3 Missing Data (Paediatrics)

Table 5.3.1 Overall missing data (Paediatrics)

	0 and ≤5	>5 and ≤10	>10 and ≤15	>15 and ≤20	>20 and ≤40	>40
Missing data	86.3%	7.5%	0.0%	0.0%	0.0%	6.3%

Table 5.3.2 Missing data by field (Paediatrics)










Item no.	Clinical Parameters	2021 (n=412)		2019 (n=371)	
		n	%	n	%
Demographics					
1.1	Date of birth	0	0.0	0	0.0
1.2	Gender	0	0.0	0	0.0
1.2.1	Currently pregnant (females aged 12-<18 years)	0	0.0	0	0.0
1.3	Date of visit	0	0.0	0	0.0
1.4	Initial visit	2	0.5	1	0.3
1.5	Aboriginal/Torres Strait Islander	0	0.0	0	0.0
1.6	Country of birth	0	0.0	0	0.0
1.7	NDSS	0	0.0	0	0.0
1.8	DVA	0	0.0	0	0.0
Diabetes type and management					
2.1	Year of diagnosis	4	1.0	1	0.3
2.2	Type of diabetes	1	0.2	1	0.3
2.3	Blood glucose monitoring	5	1.2	1	0.3
2.4	Management method	4	1.0	0	0.0
2.4.1	Years on insulin	8	0.2	6	1.6
2.4.2	Insulin mode	3	0.1	9	2.4
Height, weight and smoking status					
3.1	Weight	19	4.6	0	0.0
3.2	Height	24	5.8	1	0.3
3.3	Smoking status	0	0.0	3	0.8
3.3.1	Number of years spent smoking (current or past smokers)	0	0.0	0	0.0
Blood pressure					
4.1	Blood pressure - systolic	270	65.5	193	52.0
4.1	Blood pressure - diastolic	270	65.5	193	52.0
4.2	On anti-hypertensive treatment	1	0.2	0	0.0
Diabetes related eye disease					
5.1	Attended optometrist/ophthalmologist	2	1.0	1	0.3
5.2	Fundus examination	4	1.0	1	0.3
5.3	Retinopathy	4	1.0	1	0.3
5.4	Treatment for retinopathy	3	0.7	1	0.3
5.5	Right or left cataract	3	0.7	1	0.3
Diabetes related foot problems					
6.1	Peripheral neuropathy - last 12 months	1	0.2	0	0.0
	Peripheral neuropathy - previous	7	1.7	0	0.0
6.2	Foot ulceration - last 12 months	1	0.2	0	0.0
	Foot ulceration - previous	7	1.7	0	0.0
6.3	Peripheral vascular disease - last 12 months	1	0.2	0	0.0
	Peripheral vascular disease - previous	7	1.7	0	0.0
6.4	Lower limb amputation - last 12 months	372	90.3	0	0.0
	Lower limb amputation - previous	378	91.7	0	0.0
Medications and lipids					
7.1	Aspirin	1	0.2	0	0.0
7.2	Other anti-platelets	1	0.2	0	0.0
7.3	Anti-coagulants	2	0.5	0	0.0
7.4	On lipid lowering therapy	1	0.2	0	0.0
7.4.1	On lipid lowering therapy - Statin	0	0.0	0	0.0
7.4.2	On lipid lowering therapy - Fibrate	0	0.0	0	0.0
7.4.3	On lipid lowering therapy - Ezetimibe	0	0.0	0	0.0
7.4.4	On lipid lowering therapy - Fish oil	0	0.0	0	0.0

Item no.	Clinical Parameters	n	%	n	%
7.5	Lipids measured	0	0.0	2	0.5
7.5.1	Lipids measured - Total cholesterol	0	0.0	0	0.0
7.5.2	Lipids measured - LDL cholesterol	31	7.5	20	5.4
7.5.3	Lipids measured - HDL cholesterol	29	7.0	16	4.3
7.5.4	Lipids measured - Triglycerides	3	0.7	0	0.0
7.5.5	Lipids measured - Fasting lipids	1	0.2	0	0.0
Complications/events/comorbidities					
8.1	Stroke - last 12 months	3	0.7	0	0.0
	Stroke - previous	4	1.0	0	0.0
8.2	Myocardial infarction - last 12 months	3	0.7	0	0.0
	Myocardial infarction - previous	4	1.0	0	0.0
8.3	CABG - last 12 months	3	0.7	0	0.0
	CABG - previous	4	1.0	0	0.0
8.4	Congestive cardiac failure - last 12 months	3	0.7	0	0.0
	Congestive cardiac failure - previous	4	1.0	0	0.0
8.5	End stage renal disease - last 12 months	3	0.7	0	0.0
	End stage renal disease - previous	4	1.0	0	0.0
8.6	Blindness - last 12 months	3	0.7	0	0.0
	Blindness - previous	4	1.0	0	0.0
8.7	Sexual dysfunction - last 12 months	3	0.7	0	0.0
	Sexual dysfunction - previous	4	1.0	0	0.0
8.8	Dementia - last 12 months	3	0.7	0	0.0
	Dementia - previous	4	1.0	0	0.0
8.9	Diabetic ketoacidosis - last 12 months	3	0.7	0	0.0
	Diabetic ketoacidosis - previous	5	1.2	2	0.5
8.10	Hyperosmolar hyperglycaemic state - last 12 months	5	1.2	0	0.0
	Hyperosmolar hyperglycaemic state - previous	7	1.7	1	0.3
8.11	Severe hypoglycaemia - last 12 months	5	1.2	3	0.8
	Severe hypoglycaemia - last 12 months - No. of episodes	1	6.3	0	0.0
	Severe hypoglycaemia - previous	7	1.7	21	5.7
8.12	Malignancy	3	0.7	1	0.3
8.13	Liver disease	8	1.9	1	0.3
Renal function and blood glucose control					
9.1	Urinary protein/albumin collected	3	0.7	0	0.0
9.1.1	Urinary protein/albumin result	0	0.0	0	0.0
9.1.2	Urinary protein/albumin unit	0	0.0	0	0.0
9.2	Serum creatinine	391	94.9	352	94.9
9.3.1	Glycated haemoglobin reported (%)	35	8.5	43	11.6
9.3.2	Glycated haemoglobin reported (mmol/mol)	30	7.3	15	4.0

6.1 Descriptive Report (Adults)


Mean age, BMI and duration by diabetes type

Diabetes type	Age (years)					BMI (kg/m ²)					Duration (years)				
	n	Mean	SD	Min	Max	n	Mean	SD	Min	Max	n	Mean	SD	Min	Max
T1DM	1304	43.6	17.4	18.0	86.5	1153	27.7	5.7	15.8	53.1	1266	20.5	14.2	0.0	68.0
T2DM	3025	63.7	13.3	18.5	93.9	2767	33.3	7.9	16.5	101.6	2914	14.3	10.0	0.0	68.0
Don't know	26	49.9	17.2	20.2	79.6	23	28.5	6.8	18.8	42.3	24	8.4	10.1	0.0	33.0
Other	110	57.4	15.2	18.8	85.4	96	27.5	6.9	17.7	60.0	106	10.4	10.5	0.0	47.0
Unstated	19	55.5	18.6	20.6	81.3	12	27.9	5.3	20.7	39.1	14	19.8	11.9	2.0	36.0
Total	4484	57.6	17.3	18.0	93.9	4051	31.5	7.7	15.8	101.6	4324	16.0	11.8	0.0	68.0









BMI by diabetes type

Diabetes type	<25 (kg/m ²)			25-30 (kg/m ²)			≥30 (kg/m ²)			Total	
	n	R%	C%	n	R%	C%	n	R%	C%	n	%
T1DM	427	37.0	54.6	403	35.0	33.9	323	28.0	15.5	1153	28.5
T2DM	306	11.1	39.1	746	27.0	62.7	1715	62.0	82.5	2767	68.3
Don't know	7	30.4	0.9	7	30.4	0.6	9	39.1	0.4	23	0.6
Other	37	38.5	4.7	31	32.3	2.6	28	29.2	1.3	96	2.4
Unstated	5	41.7	0.6	3	25.0	0.3	4	33.3	0.2	12	0.3
Total	782	19.3		1190	29.4		2079	51.3		4051	



Gender by diabetes type







Diabetes type	Males			Females			Total	
	n	R%	C%	n	R%	C%	n	%
T1DM	611	47.4	25.3	679	52.6	33.7	1290	29.1
T2DM	1722	57.5	71.2	1272	42.5	63.1	2994	67.5
Don't know	13	50.0	0.5	13	50.0	0.6	26	0.6
Other	67	62.0	2.8	41	38.0	2.0	108	2.4
Unstated	5	29.4	0.2	12	70.6	0.6	17	0.4
Total	2418	54.5		2017	45.5		4435	



Currently pregnant* by diabetes type







Diabetes type	Yes			No			Total	
	n	R%	C%	n	R%	C%	n	%
T1DM	35	7.3	71.4	446	92.7	55.3	481	56.3
T2DM	14	4.0	28.6	332	96.0	41.2	346	40.5
Don't know	0	0.0	0.0	8	100.0	1.0	8	0.9
Other	0	0.0	0.0	20	100.0	2.5	20	2.3
Unstated	NA	NA	NA	NA	NA	NA	NA	NA
Total	49	5.7		806	94.3		855	

* females aged 18-55 years









Initial visit by diabetes type

Diabetes type	Yes			No			Total	
	n	R%	C%	n	R%	C%	n	%
T1DM	132	10.5	21.6	1124	89.5	30.0	1256	28.8
T2DM	457	15.4	74.9	2503	84.6	66.7	2960	67.9
Don't know	4	15.4	0.7	22	84.6	0.6	26	0.6
Other	16	15.2	2.6	89	84.8	2.4	105	2.4
Unstated	1	7.7	0.2	12	92.3	0.3	13	0.3
Total	610	14.0		3750	86.0		4360	






Aboriginal/Torres Strait Islander status by diabetes type

Diabetes type	Yes			No			Total	
	n	R%	C%	n	R%	C%	n	%
T1DM	41	3.2	26.6	1233	96.8	29.1	1274	29.0
T2DM	110	3.7	71.4	2870	96.3	67.6	2980	67.8
Don't know	0	0.0	0.0	24	100.0	0.6	24	0.5
Other	3	2.8	1.9	104	97.2	2.5	107	2.4
Unstated	0	0.0	0.0	13	100.0	0.3	13	0.3
Total	154	3.5		4244	96.5		4398	






Australian born by diabetes type

Diabetes type	Yes			No			Total	
	n	R%	C%	n	R%	C%	n	%
T1DM	1047	81.5	33.5	237	18.5	18.6	1284	29.2
T2DM	1969	66.5	63.0	992	33.5	78.0	2961	67.4
Don't know	19	76.0	0.6	6	24.0	0.5	25	0.6
Other	74	69.8	2.4	32	30.2	2.5	106	2.4
Unstated	15	78.9	0.5	4	21.1	0.3	19	0.4
Total	3124	71.1		1271	28.9		4395	



NDSS by diabetes type


Diabetes type	Yes			No			Total	
	n	R%	C%	n	R%	C%	n	%
T1DM	1220	97.1	30.2	36	2.9	14.1	1256	29.3
T2DM	2695	93.0	66.7	204	7.0	79.7	2899	67.5
Don't know	19	79.2	0.5	5	20.8	2	24	0.6
Other	93	90.3	2.3	10	9.7	3.9	103	2.4
Unstated	11	91.7	0.3	1	8.3	0	12	0.3
Total	4038	94.0		256	6.0		4294	



Methods of blood glucose monitoring*

Diabetes type	None			Finger prick			Continuous			Flash			Total	
	n	R%	C%	n	R%	C%	n	R%	C%	n	R%	C%	n	%
T1DM	12	1.0	2.2	805	69.3	23.4	345	29.7	92.5	327	28.1	80.7	1162	28.0
T2DM	316	11.0	57.8	2527	88.3	73.5	20	0.7	5.4	56	2.0	13.8	2863	69.0
Don't know	2	9.5	0.4	17	81.0	0.5	2	9.5	0.5	2	9.5	0.5	21	0.5
Other	5	5.9	0.9	77	90.6	2.2	3	3.5	0.8	20	23.5	4.9	85	2.0
Unstated	1	5.9	0.2	13	76.5	0.4	3	17.6	0.8	0	0.0	0.0	17	0.4
Total	336	8.1		3439	82.9		373	9.0		405	9.8		4148	

* multiple methods reported by some patients




X-axis: All sites (Descending order)

Proportion of time using blood glucose monitoring sensors*


Diabetes type	<50%			50-75%			>75-100%			Total	
	n	R%	C%	n	R%	C%	n	R%	C%	n	%
T1DM	77	18.2	14.1	55	13.0	85.9	292	68.9	93.3	424	10.2
T2DM	18	43.9	3.3	7	17.1	10.9	16	39.0	5.1	41	1.0
Don't know	0	0.0	0.0	1	50.0	1.6	1	50.0	0.3	2	0.0
Other	1	20.0	0.2	1	20.0	1.6	3	60.0	1.0	5	0.1
Unstated	0	0.0	0.0	0	0.0	0.0	1	100.0	0.3	1	0.0
Total	96	20.3		64	13.5		313	66.2		473	

* of patients using flash/continuous glucose monitoring



Smoking status by diabetes type

Diabetes type	Current smoker			Past smoker			Never smoked			Total	
	n	R%	C%	n	R%	C%	n	R%	C%	n	%
T1DM	154	12.2	31.1	286	22.7	20.7	822	65.1	33.5	1262	29.1
T2DM	318	10.8	64.2	1059	36.1	76.5	1555	53.0	63.3	2932	67.7
Don't know	5	20.8	1.0	3	12.5	0.2	16	66.7	0.7	24	0.6
Other	17	16.3	3.4	33	31.7	2.4	54	51.9	2.2	104	2.4
Unstated	1	8.3	0.2	3	25.0	0.2	8	66.7	0.3	12	0.3
Total	495	11.4		1384	31.9		2455	56.6		4334	















X-axis: All sites (Descending order)

Number of years spent smoking (current or past smokers) by diabetes type

Diabetes type	<5 years			5-10 years			11-20 years			>20 years			Total	
	n	R%	C%	n	R%	C%	n	R%	C%	n	R%	C%	n	%
T1DM	84	20.4	37.8	86	20.9	30.9	99	24.1	24.8	142	34.5	16.6	411	23.4
T2DM	132	10.3	59.5	181	14.1	65.1	292	22.7	73.2	679	52.9	79.3	1284	73.2
Don't know	1	12.5	0.5	2	25.0	0.7	1	12.5	0.3	4	50.0	0.5	8	0.5
Other	5	10.4	2.3	7	14.6	2.5	6	12.5	1.5	30	62.5	3.5	48	2.7
Unstated	0	0.0	0.0	2	50.0	0.7	1	25.0	0.3	1	25.0	0.1	4	0.2
Total	222	12.6		278	15.8		399	22.7		856	48.8		1755	





*of patients who are current and past smokers





Age by blood pressure level


Age	≤130/80		>130/80		≤140/90		>140/90	
	n	C%	n	C%	n	C%	n	C%
≤60 years	862	51.6	986	44.9	1413	51.5	434	38.7
>60 years	807	48.4	1210	55.1	1329	48.5	688	61.3
Total	1669		2196		2742		1122	









Treatment by diabetes type

Diabetes type	Diet only			Tablets			Insulin			Insulin & tablets			Injectables		
	n	R%	C%	n	R%	C%	n	R%	C%	n	R%	C%	n	R%	C%
T1DM	3	0.2	2.5	3	0.2	0.3	1143	87.7	78.0	108	8.3	9.3	0	0.0	0.0
T2DM	113	3.7	92.6	940	31.1	97.4	252	8.3	17.2	1015	33.6	87.5	10	0.3	100.0
Don't know	3	11.5	2.5	3	11.5	0.3	7	26.9	0.5	10	38.5	0.9	0	0.0	0.0
Other	3	2.7	2.5	17	15.5	1.8	59	53.6	4.0	24	21.8	2.1	0	0.0	0.0
Unstated	0	0.0	0.0	2	10.5	0.2	5	26.3	0.3	3	15.8	0.3	0	0.0	0.0
Total	122	2.7		965	21.5		1466	32.7		1160	25.9		10	0.2	

Diabetes type	Injectables & insulin (not graphed)			Injectables & tablets			Injectables, tablets & insulin			Unstated (not graphed)			Total	
	n	R%	C%	n	R%	C%	n	R%	C%	n	R%	C%	n	%
T1DM	28	2.1	57.1	0	0.0	0.0	10	0.8	18.5	9	0.7	2.9	1304	29.1
T2DM	13	0.4	26.5	343	11.3	98.6	43	1.4	79.6	296	9.8	95.5	3025	67.5
Don't know	0	0.0	0.0	1	3.8	0.3	1	3.8	1.9	1	3.8	0.3	26	0.6
Other	2	1.8	4.1	3	2.7	0.9	0	0.0	0.0	2	1.8	0.6	110	2.5
Unstated	6	31.6	12.2	1	5.3	0.3	0	0.0	0.0	2	10.5	0.6	19	0.4
Total	49	1.1		348	7.8		54	1.2		310	6.9		4484	











Modes of insulin by diabetes type*










Diabetes type	Basal			Basal bolus			Pump			Pre-mixed insulin			Hybrid System		
	n	R%	C%	n	R%	C%	n	R%	C%	n	R%	C%	n	R%	C%
T1DM	71	5.6	13.0	818	64.9	58.6	364	887.8	97.6	66	5.2	8.4	41	3.3	91.1
T2DM	461	29.0	84.3	509	32.0	36.5	6	300.0	1.6	697	43.8	89.1	2	0.1	4.4
Don't know	5	27.8	0.9	10	55.6	0.7	0	0.0	0.0	3	16.7	0.4	0	0.0	0.0
Other	10	12.0	1.8	59	71.1	4.2	3	150.0	0.8	16	19.3	2.0	2	2.4	4.4
Unstated	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Total	547	18.5		1396	47.3		373	12.6		782	26.5		45	1.5	

* patients taking insulin (multiple modes of insulin were reported for some patients)






Diabetes type	Total	
	n	%
T1DM	1261	42.7
T2DM	1591	53.9
Don't know	18	0.6
Other	83	2.8
Unstated	NA	NA
Total	2953	





HbA1c (%) by diabetes type




Diabetes type	n	Mean	SD	Min	Max
T1DM	1237	8.4	1.7	2.2	16.0
T2DM	2881	8.2	1.8	4.4	17.9
Don't know	26	8.5	2.6	5.1	14.0
Other	104	8.2	2.1	4.6	15.2
Unstated	14	7.4	1.2	5.4	8.9
Total	4262	8.3	1.7	2.2	17.9



X-axis: All sites (Descending order)


HbA1c (%) and initial visit by diabetes type

Diabetes type	HbA1c when initial visit = No				
	n	Mean	SD	Min	Max
T1DM	1066	8.3	1.6	2.2	16.0
T2DM	2391	8.1	1.7	4.4	17.9
Don't know	22	8.2	2.6	2.2	14.0
Other	84	8.1	2.0	2.2	14.8
Unstated	8	7.4	1.2	2.2	8.9
Total	3571	8.2	1.7	2.2	17.9












Mean total cholesterol, HDL cholesterol and triglycerides by diabetes type

Diabetes type	Total cholesterol					HDL					Triglycerides				
	n	Mean	SD	Min	Max	n	Mean	SD	Min	Max	n	Mean	SD	Min	Max
T1DM	771	4.6	1.1	2.1	10.4	635	1.5	0.4	0.0	4.5	730	1.3	1.1	0.3	11.8
T2DM	2222	4.2	1.2	1.4	16.6	1989	1.1	0.4	0.0	5.6	2173	2.3	2.0	0.3	36.9
Don't know	16	4.4	1.1	2.1	6.5	13	1.2	0.3	0.0	1.9	15	1.7	1.1	0.3	4.4
Other	69	4.5	1.2	2.1	7.6	62	1.2	0.4	0.0	2.5	66	2.3	2.5	0.3	15.6
Unstated	10	4.5	1.4	2.1	7.2	10	1.4	0.8	0.0	3.4	11	1.7	1.6	0.3	5.6
Total	3088	4.3	1.2	1.4	16.6	2709	1.2	0.4	0.0	5.6	2995	2.0	1.9	0.3	36.9









Mean total cholesterol, HDL cholesterol and triglycerides (fasting) by diabetes type

Diabetes type	Total cholesterol					HDL					Triglycerides				
	n	Mean	SD	Min	Max	n	Mean	SD	Min	Max	n	Mean	SD	Min	Max
T1DM	550	4.6	1.1	2.1	10.4	471	1.5	0.5	0.0	4.5	528	1.2	1.0	0.3	10.0
T2DM	1803	4.1	1.2	1.4	16.6	1638	1.1	0.4	0.0	4.8	1776	2.3	2.0	0.3	36.9
Don't know	11	4.3	1.1	1.9	6.2	10	1.2	0.4	0.7	1.9	11	1.5	1.1	0.4	4.4
Other	51	4.5	1.2	2.4	7.6	48	1.3	0.4	0.4	2.5	51	1.9	1.9	0.6	12.6
Unstated	6	4.2	0.7	3.4	5.1	5	1.3	0.4	0.7	1.8	6	2.0	1.9	0.7	5.6
Total	2421	4.2	1.2	1.4	16.6	2172	1.2	0.4	0.0	4.8	2372	2.0	1.9	0.3	36.9









Total cholesterol by diabetes type

Diabetes type	<4.0 (mmol/L)			≥4.0 (mmol/L)			Total	
	n	R%	C%	n	R%	C%	n	%
T1DM	233	30.2	17.2	538	69.8	31.0	771	25.0
T2DM	1085	48.8	80.3	1137	51.2	65.5	2222	72.0
Don't know	5	31.3	0.4	11	68.8	0.6	16	0.5
Other	25	36.2	1.8	44	63.8	2.5	69	2.2
Unstated	4	40.0	0.3	6	60.0	0.3	10	0.3
Total	1352	43.8		1736	56.2		3088	









Total cholesterol (fasting) by diabetes type

Diabetes type	<4.0 (mmol/L)			≥4.0 (mmol/L)			Total	
	n	R%	C%	n	R%	C%	n	%
T1DM	174	31.6	15.7	376	68.4	28.6	550	22.7
T2DM	909	50.4	82.1	894	49.6	68.0	1803	74.5
Don't know	3	27.3	0.3	8	72.7	0.6	11	0.5
Other	18	35.3	1.6	33	64.7	2.5	51	2.1
Unstated	3	50.0	0.3	3	50.0	0.2	6	0.2
Total	1107	45.7		1314	54.3		2421	









HDL cholesterol by diabetes type

Diabetes type	<1.0 (mmol/L)			≥1.0 (mmol/L)			Total	
	n	R%	C%	n	R%	C%	n	%
T1DM	46	7.2	6.1	589	92.8	30.1	635	23.4
T2DM	688	34.6	91.2	1301	65.4	66.5	1989	73.4
Don't know	3	23.1	0.4	10	76.9	0.5	13	0.5
Other	15	24.2	2.0	47	75.8	2.4	62	2.3
Unstated	2	20.0	0.3	8	80.0	0.4	10	0.4
Total	754	27.8		1955	72.2		2709	









HDL cholesterol (fasting) by diabetes type

Diabetes type	<1.0 (mmol/L)			≥1.0 (mmol/L)			Total	
	n	R%	C%	n	R%	C%	n	%
T1DM	33	7.0	5.3	438	93.0	28.3	471	21.7
T2DM	574	35.0	92.3	1064	65.0	68.6	1638	75.4
Don't know	2	20.0	0.3	8	80.0	0.5	10	0.5
Other	12	25.0	1.9	36	75.0	2.3	48	2.2
Unstated	1	20.0	0.2	4	80.0	0.3	5	0.2
Total	622	28.6		1550	71.4		2172	









Triglycerides by diabetes type

Diabetes type	<2.0 (mmol/L)			≥2.0 (mmol/L)			Total	
	n	R%	C%	n	R%	C%	n	%
T1DM	628	86.0	33.9	102	14.0	8.9	730	24.4
T2DM	1166	53.7	62.9	1007	46.3	88.3	2173	72.6
Don't know	11	73.3	0.6	4	26.7	0.4	15	0.5
Other	41	62.1	2.2	25	37.9	2.2	66	2.2
Unstated	8	72.7	0.4	3	27.3	0.3	11	0.4
Total	1854	61.9		1141	38.1		2995	






Triglycerides (fasting) by diabetes type

Diabetes type	<2.0 (mmol/L)			≥2.0 (mmol/L)			Total	
	n	R%	C%	n	R%	C%	n	%
T1DM	463	87.7	31.3	65	12.3	7.3	528	22.3
T2DM	969	54.6	65.5	807	45.4	90.5	1776	74.9
Don't know	9	81.8	0.6	2	18.2	0.2	11	0.5
Other	35	68.6	2.4	16	31.4	1.8	51	2.2
Unstated	4	66.7	0.3	2	33.3	0.2	6	0.3
Total	1480	62.4		892	37.6		2372	



Mean LDL cholesterol by diabetes type




Diabetes type	LDL				
	n	Mean	SD	Min	Max
T1DM	642	2.5	1.0	0.0	7.3
T2DM	1940	2.1	1.0	0.0	7.9
Don't know	13	2.2	0.7	0.0	3.2
Other	58	2.3	1.0	0.0	5.2
Unstated	9	2.1	0.6	0.0	2.7
Total	2662	2.2	1.0	0.0	7.9



X-axis: All sites (Descending order)

Mean LDL cholesterol (fasting) by diabetes type







Diabetes type	LDL				
	n	Mean	SD	Min	Max
T1DM	477	2.5	0.9	0.0	7.3
T2DM	1603	2.1	1.0	0.0	7.9
Don't know	10	2.3	0.7	1.1	3.2
Other	47	2.4	1.0	1.0	5.2
Unstated	4	2.1	0.8	1.1	2.7
Total	2141	2.2	1.0	0.0	7.9



X-axis: All sites (Descending order)







LDL cholesterol by diabetes type

Diabetes type	<2.0 (mmol/L)			≥2.0 (mmol/L)			Total	
	n	R%	C%	n	R%	C%	n	%
T1DM	202	31.5	16.1	440	68.5	31.2	642	24.1
T2DM	1015	52.3	81.1	925	47.7	65.6	1940	72.9
Don't know	6	46.2	0.5	7	53.8	0.5	13	0.5
Other	25	43.1	2.0	33	56.9	2.3	58	2.2
Unstated	3	33.3	0.2	6	66.7	0.4	9	0.3
Total	1251	47.0		1411	53.0		2662	






LDL cholesterol (fasting) by diabetes type

Diabetes type	<2.0 (mmol/L)			≥2.0 (mmol/L)			Total	
	n	R%	C%	n	R%	C%	n	%
T1DM	159	33.3	15.4	318	66.7	28.6	477	22.3
T2DM	846	52.8	82.1	757	47.2	68.1	1603	74.9
Don't know	4	40.0	0.4	6	60.0	0.5	10	0.5
Other	19	40.4	1.8	28	59.6	2.5	47	2.2
Unstated	2	50.0	0.2	2	50.0	0.2	4	0.2
Total	1030	48.1		1111	51.9		2141	






Diabetic ketoacidosis (last 12 months) by diabetes type

Diabetes type	Yes			No (Not graphed)			Total	
	n	R%	C%	n	R%	C%	n	%
T1DM	93	7.3	75.0	1183	92.7	28.2	1276	28.7
T2DM	25	0.9	20.2	2873	99.1	68.5	2898	65.1
Don't know	2	8.3	1.6	22	91.7	0.5	24	0.5
Other	3	2.9	2.4	99	97.1	2.4	102	2.3
Unstated	1	5.9	0.8	16	94.1	0.4	17	0.4
Total	124	2.9		4193	97.1		4317	






Hyperosmolar hyperglycaemic state (last 12 months) by diabetes type

Diabetes type	Yes			No (Not graphed)			Total	
	n	R%	C%	n	R%	C%	n	%
T1DM	3	0.2	8.6	1270	99.8	29.7	1273	28.6
T2DM	28	1.0	80.0	2867	99.0	67.0	2895	65.1
Don't know	0	0.0	0.0	24	100.0	0.6	24	0.5
Other	4	3.9	11.4	98	96.1	2.3	102	2.3
Unstated	0	0.0	0.0	17	100.0	0.4	17	0.4
Total	35	0.8		4276	99.2		4311	




Severe hypoglycaemia (last 12 months) by diabetes type

Diabetes type	Yes			No (Not graphed)			Total	
	n	R%	C%	n	R%	C%	n	%
T1DM	113	8.8	56.8	1168	91.2	27.6	1281	28.8
T2DM	72	2.4	36.2	2920	97.6	69.1	2992	67.2
Don't know	3	11.5	1.5	23	88.5	0.5	26	0.6
Other	7	6.5	3.5	101	93.5	2.4	108	2.4
Unstated	4	23.5	2.0	13	76.5	0.3	17	0.4
Total	199	4.5		4225	95.5		4424	



Urinary albumin by diabetes type










Diabetes type	Normoalbuminuria			Microalbuminuria			Macroalbuminuria			Total	
	n	R%	C%	n	R%	C%	n	R%	C%	n	%
T1DM	543	77.0	34.6	121	17.2	16.9	41	5.8	16.1	705	27.8
T2DM	978	55.5	62.3	576	32.7	80.7	208	11.8	81.9	1762	69.5
Don't know	9	100.0	0.6	0	0.0	0.0	0	0.0	0.0	9	0.4
Other	36	65.5	2.3	15	27.3	2.1	4	7.3	1.6	55	2.2
Unstated	3	50.0	0.2	1	16.7	0.1	1	16.7	0.4	6	0.2
Total	1569	61.8		714	28.1		254	10.0		2537	



X-axis: All sites (Descending order)










Serum creatinine levels by diabetes type

Diabetes type	<120 (μmol/L)			≥120 - ≤500 (μmol/L)			>500 (μmol/L)			Total	
	n	R%	C%	n	R%	C%	n	R%	C%	n	%
T1DM	970	92.5	29.8	70	6.7	13.2	9	0.9	23.1	1049	27.4
T2DM	2184	82.4	67.2	440	16.6	82.7	28	1.1	71.8	2652	69.4
Don't know	17	89.5	0.5	2	10.5	0.4	0	0.0	0.0	19	0.5
Other	74	80.4	2.3	17	18.5	3.2	1	1.1	2.6	92	2.4
Unstated	6	60.0	0.2	3	30.0	0.6	1	10.0	2.6	10	0.3
Total	3251	85.1		532	13.9		39	1.0		3822	



Number of complications by diabetes type


Diabetes type	0			1-2			≥3			Total	
	n	R%	C%	n	R%	C%	n	R%	C%	n	%
T1DM	779	73.1	37.3	214	20.1	19.5	72	6.8	16.2	1065	29.3
T2DM	1241	50.8	59.4	839	34.4	76.6	362	14.8	81.5	2442	67.3
Don't know	17	73.9	0.8	4	17.4	0.4	2	8.7	0.5	23	0.6
Other	48	53.3	2.3	35	38.9	3.2	7	7.8	1.6	90	2.5
Unstated	5	55.6	0.2	3	33.3	0.3	1	11.1	0.2	9	0.2
Total	2090	57.6		1095	30.2		444	12.2		3629	



Number of vascular complications* by diabetes type

Diabetes type	0			1-2			≥3			Total	
	n	R%	C%	n	R%	C%	n	R%	C%	n	%
T1DM	1158	91.5	33.0	102	8.1	13.0	6	0.5	12.2	1266	29.2
T2DM	2228	76.0	63.5	659	22.5	83.9	43	1.5	87.8	2930	67.5
Don't know	20	76.9	0.6	6	23.1	0.8	0	0.0	0.0	26	0.6
Other	91	86.7	2.6	14	13.3	1.8	0	0.0	0.0	105	2.4
Unstated	10	71.4	0.3	4	28.6	0.5	0	0.0	0.0	14	0.3
Total	3507	80.8		785	18.1		49	1.1		4341	










*possible complications include macrovascular/microvascular complications. Occurrence of a complication, both in the past 12 months and previously, is counted only once.



Number of vascular complications* (current smokers) by diabetes type

Diabetes type	0			1-2			≥3			Total	
	n	R%	C%	n	R%	C%	n	R%	C%	n	%
T1DM	137	90.7	33.9	14	9.3	18.2	0	0.0	0.0	151	31.1
T2DM	247	78.9	61.1	61	19.5	79.2	5	1.6	100.0	313	64.4
Don't know	4	80.0	1.0	1	20.0	1.3	0	0.0	0.0	5	1.0
Other	15	93.8	3.7	1	6.3	1.3	0	0.0	0.0	16	3.3
Unstated	1	100.0	0.2	0	0.0	0.0	0	0.0	0.0	1	0.2
Total	404	83.1		77	15.8		5	1.0		486	

*possible complications include macrovascular/microvascular complications. Occurrence of a complication, both in the past 12 months and previously, is counted only once.




X-axis: All sites (Descending order)

Number of vascular complications* (past smokers) by diabetes type

Diabetes type	0			1-2			≥3			Total	
	n	R%	C%	n	R%	C%	n	R%	C%	n	%
T1DM	233	83.8	24.2	40	14.4	11.4	5	1.8	22.7	278	20.8
T2DM	702	68.7	72.8	303	29.6	86.1	17	1.7	77.3	1022	76.4
Don't know	1	33.3	0.1	NA	NA	NA	0	0.0	0.0	3	0.2
Other	25	78.1	2.6	7	21.9	2.0	0	0.0	0.0	32	2.4
Unstated	3	100.0	0.3	0	0.0	0.0	0	0.0	0.0	3	0.2
Total	964	72.0		352	26.3		22	1.6		1338	


*possible complications include macrovascular/microvascular complications. Occurrence of a complication, both in the past 12 months and previously, is counted only once.



Number of vascular complications* (never smoked) by diabetes type

Diabetes type	0			1-2			≥3			Total	
	n	R%	C%	n	R%	C%	n	R%	C%	n	%
T1DM	757	94.2	37.1	46	5.7	13.9	1	0.1	5.3	804	33.6
T2DM	1221	80.6	59.8	275	18.2	82.8	18	1.2	94.7	1514	63.3
Don't know	13	81.3	0.6	3	18.8	0.9	0	0.0	0.0	16	0.7
Other	48	92.3	2.4	4	7.7	1.2	0	0.0	0.0	52	2.2
Unstated	3	42.9	0.1	4	57.1	1.2	0	0.0	0.0	7	0.3
Total	2042	85.3		332	13.9		19	0.8		2393	







*possible complications include macrovascular/microvascular complications. Occurrence of a complication, both in the past 12 months and previously, is counted only once.



X-axis: All sites (Descending order)







ACE inhibitor use by diabetes type

Diabetes type	Yes			No			Total	
	n	R%	C%	n	R%	C%	n	%
T1DM	223	17.1	18.6	1081	82.9	32.9	1304	29.1
T2DM	941	31.1	78.6	2084	68.9	63.4	3025	67.5
Don't know	10	38.5	0.8	16	61.5	0.5	26	0.6
Other	18	16.4	1.5	92	83.6	2.8	110	2.5
Unstated	5	26.3	0.4	14	73.7	0.4	19	0.4
Total	1197	26.7		3287	73.3		4484	









ARB use by diabetes type

Diabetes type	Yes			No			Total	
	n	R%	C%	n	R%	C%	n	%
T1DM	114	8.8	11.5	1188	91.2	34.0	1302	29.0
T2DM	852	28.2	86.1	2173	71.8	62.2	3025	67.5
Don't know	3	11.5	0.3	23	88.5	0.7	26	0.6
Other	17	15.5	1.7	93	84.5	2.7	110	2.5
Unstated	3	15.8	0.3	16	84.2	0.5	19	0.4
Total	989	22.1		3493	77.9		4482	









Beta blocker use by diabetes type

Diabetes type	Yes			No			Total	
	n	R%	C%	n	R%	C%	n	%
T1DM	97	7.5	12.0	1205	92.5	32.8	1302	29.0
T2DM	683	22.6	84.8	2342	77.4	63.7	3025	67.5
Don't know	2	7.7	0.2	24	92.3	0.7	26	0.6
Other	20	18.2	2.5	90	81.8	2.4	110	2.5
Unstated	3	15.8	0.4	16	84.2	0.4	19	0.4
Total	805	18.0		3677	82.0		4482	



Calcium channel antagonist use by diabetes type







Diabetes type	Yes			No			Total	
	n	R%	C%	n	R%	C%	n	%
T1DM	107	8.2	12.9	1195	91.8	32.7	1302	29.0
T2DM	698	23.1	84.0	2327	76.9	63.7	3025	67.5
Don't know	6	23.1	0.7	20	76.9	0.5	26	0.6
Other	18	16.4	2.2	92	83.6	2.5	110	2.5
Unstated	2	10.5	0.2	17	89.5	0.5	19	0.4
Total	831	18.5		3651	81.5		4482	



X-axis: All sites (Descending order)

Thiazide use by diabetes type







Diabetes type	Yes			No			Total	
	n	R%	C%	n	R%	C%	n	%
T1DM	39	3.0	11.2	1265	97.0	30.6	1304	29.1
T2DM	306	10.1	87.7	2718	89.9	65.7	3024	67.5
Don't know	0	0.0	0.0	26	100.0	0.6	26	0.6
Other	3	2.7	0.9	107	97.3	2.6	110	2.5
Unstated	1	5.3	0.3	18	94.7	0.4	19	0.4
Total	349	7.8		4134	92.2		4483	



X-axis: All sites (Descending order)







Other anti-hypertensive therapy by diabetes type

Diabetes type	Yes			No			Total	
	n	R%	C%	n	R%	C%	n	%
T1DM	47	3.6	12.2	1255	96.4	30.6	1302	29.1
T2DM	329	10.9	85.7	2695	89.1	65.8	3024	67.5
Don't know	0	0.0	0.0	26	100.0	0.6	26	0.6
Other	8	7.3	2.1	102	92.7	2.5	110	2.5
Unstated	0	0.0	0.0	19	100.0	0.5	19	0.4
Total	384	8.6		4097	91.4		4481	



Lipid lowering therapy by diabetes type


Diabetes type	Yes			No			Total	
	n	R%	C%	n	R%	C%	n	%
T1DM	451	34.8	16.4	846	65.2	49.1	1297	29.0
T2DM	2232	73.9	81.2	789	26.1	45.8	3021	67.6
Don't know	13	50.0	0.5	13	50.0	0.8	26	0.6
Other	41	37.6	1.5	68	62.4	3.9	109	2.4
Unstated	11	64.7	0.4	6	35.3	0.3	17	0.4
Total	2748	61.5		1722	38.5		4470	



Statin* use by diabetes type

Diabetes type	Yes			No			Contraindicated (Not graphed)			Total	
	n	R%	C%	n	R%	C%	n	R%	C%	n	%
T1DM	414	92.4	16.3	27	6.0	16.2	7	1.6	24.1	448	16.4
T2DM	2072	93.0	81.4	134	6.0	80.2	21	0.9	72.4	2227	81.3
Don't know	12	92.3	0.5	1	7.7	0.6	0	0.0	0.0	13	0.5
Other	37	92.5	1.5	3	7.5	1.8	1	2.5	3.4	40	1.5
Unstated	9	81.8	0.4	2	18.2	1.2	0	0.0	0.0	11	0.4
Total	2544	92.8		167	6.1		29	1.1		2740	



*of patients who take lipid lowering therapy



Fibrate* use by diabetes type

Diabetes type	Yes			No			Contraindicated (Not graphed)			Total	
	n	R%	C%	n	R%	C%	n	R%	C%	n	%
T1DM	52	11.9	13.2	384	88.1	16.8	0	0.0	0.0	436	16.3
T2DM	328	15.0	83.5	1848	84.7	81.0	7	0.3	100.0	2183	81.4
Don't know	1	7.7	0.3	12	92.3	0.5	0	0.0	0.0	13	0.5
Other	8	19.5	2.0	33	80.5	1.4	0	0.0	0.0	41	1.5
Unstated	4	44.4	1.0	5	55.6	0.2	0	0.0	0.0	9	0.3
Total	393	14.7		2282	85.1		7	0.3		2682	



*of patients who take lipid lowering therapy



Ezetimibe* use by diabetes type

Diabetes type	Yes			No			Contraindicated (Not graphed)			Total	
	n	R%	C%	n	R%	C%	n	R%	C%	n	%
T1DM	55	12.7	13.1	378	87.1	16.8	1	0.2	10.0	434	16.2
T2DM	359	16.5	85.5	1812	83.2	80.7	8	0.4	80.0	2179	81.2
Don't know	0	0.0	0.0	13	100.0	0.6	0	0.0	0.0	13	0.5
Other	3	7.3	0.7	37	90.2	1.6	1	2.4	10.0	41	1.5
Unstated	3	37.5	0.7	5	62.5	0.2	0	0.0	0.0	8	0.3
Total	420	15.7		2245	83.9		10	0.4		2675	



*of patients who take lipid lowering therapy



Fish oil* use by diabetes type










Diabetes type	Yes			No			Contraindicated (Not graphed)			Total	
	n	R%	C%	n	R%	C%	n	R%	C%	n	%
T1DM	19	4.4	13.9	416	95.6	16.4	0	0.0	0.0	435	16.2
T2DM	113	5.2	82.5	2061	94.7	81.3	2	0.1	100.0	2176	81.1
Don't know	0	0.0	0.0	13	100.0	0.5	0	0.0	0.0	13	0.5
Other	2	4.9	1.5	39	95.1	1.5	0	0.0	0.0	41	1.5
Unstated	3	37.5	2.2	5	62.5	0.2	0	0.0	0.0	8	0.3
Total	137	5.1		2534	94.8		2	0.1		2673	

*of patients who take lipid lowering therapy



Aspirin use by diabetes type



Diabetes type	Yes			No			Contraindicated			Total	
	n	R%	C%	n	R%	C%	n	R%	C%	n	%
T1DM	183	14.1	15.8	1109	85.5	33.7	5	0.4	26.3	1297	29.0
T2DM	946	31.4	81.8	2056	68.2	62.5	14	0.5	73.7	3016	67.5
Don't know	4	15.4	0.3	22	84.6	0.7	0	0.0	0.0	26	0.6
Other	17	15.6	1.5	92	84.4	2.8	0	0.0	0.0	109	2.4
Unstated	7	38.9	0.6	11	61.1	0.3	0	0.0	0.0	18	0.4
Total	1157	25.9		3290	73.7		19	0.4		4466	



X-axis: All sites (Descending order)

Other antiplatelet therapy by diabetes type








Diabetes type	Yes			No			Contraindicated (Not graphed)			Total	
	n	R%	C%	n	R%	C%	n	R%	C%	n	%
T1DM	31	2.4	9.6	1259	97.4	30.6	3	0.2	37.5	1293	29.1
T2DM	285	9.5	88.0	2716	90.4	66.0	4	0.1	50.0	3005	67.5
Don't know	3	11.5	0.9	23	88.5	0.6	0	0.0	0.0	26	0.6
Other	4	3.7	1.2	104	95.4	2.5	1	0.9	12.5	109	2.4
Unstated	1	5.9	0.3	16	94.1	0.4	0	0.0	0.0	17	0.4
Total	324	7.3		4118	92.5		8	0.2		4450	



Number of glucose lowering drugs by diabetes type

Diabetes type	0 (Not graphed)			1			2			3			≥4 (Not graphed)		
	n	R%	C%	n	R%	C%	n	R%	C%	n	R%	C%	n	R%	C%
T1DM	31	2.4	18.2	1145	87.8	62.1	104	8.0	10.4	21	1.6	2.0	3	0.2	0.7
T2DM	125	4.1	73.5	614	20.3	33.3	865	28.6	86.5	1024	33.9	96.2	396	13.1	97.8
Don't know	3	11.5	1.8	9	34.6	0.5	8	30.8	0.8	6	23.1	0.6	0	0.0	0.0
Other	5	4.5	2.9	71	64.5	3.9	21	19.1	2.1	10	9.1	0.9	3	2.7	0.7
Unstated	6	31.6	3.5	5	26.3	0.3	2	10.5	0.2	3	15.8	0.3	3	15.8	0.7
Total	170	3.8		1844	41.1		1000	22.3		1064	23.7		405	9.0	


Diabetes Type	Total	
	n	%
T1DM	1304	29.1
T2DM	3024	67.5
Don't know	26	0.6
Other	110	2.5
Unstated	19	0.4
Total	4483	



Number of anti-hypertensive drugs by diabetes type

Diabetes type	1			2			3			≥4 (Not graphed)			Total	
	n	R%	C%	n	R%	C%	n	R%	C%	n	R%	C%	n	%
T1DM	237	18.2	17.7	119	9.1	13.6	33	2.5	9.1	13	14.0	14.0	1304	29.1
T2DM	1055	34.9	79.0	737	24.4	84.2	318	10.5	87.8	79	2.6	84.9	3025	67.5
Don't know	7	26.9	0.5	4	15.4	0.5	2	7.7	0.6	0	0.0	0.0	26	0.6
Other	31	28.2	2.3	14	12.7	1.6	7	6.4	1.9	1	0.9	1.1	110	2.5
Unstated	6	31.6	0.4	1	5.3	0.1	2	10.5	0.6	0	0.0	0.0	19	0.4
Total	1336	29.8		875	19.5		362	8.1		93	2.1		4484	







* of patients who take anti-hypertensive therapy



X-axis: All sites (Descending order)


Liver disease by diabetes type

Diabetes type	Mild			Moderate			Nil (Not graphed)			Total	
	n	R%	C%	n	R%	C%	n	R%	C%	n	%
T1DM	32	2.6	8.4	4	0.3	3.5	1204	97.1	32.4	1240	29.4
T2DM	337	11.9	88.5	101	3.6	87.8	2395	84.5	64.4	2833	67.2
Don't know	0	0.0	0.0	0	0.0	0.0	23	100.0	0.6	23	0.5
Other	11	10.9	2.9	9	8.9	7.8	81	80.2	2.2	101	2.4
Unstated	1	6.3	0.3	1	6.3	0.9	14	87.5	0.4	16	0.4
Total	381	9.0		115	2.7		3717	88.2		4213	




6.2 Descriptive Report (GDM)




Age: There were 163 patients with GDM who had age recorded. The mean age was 32.8 (SD \pm 4.8) years.




BMI: There were 142 patients with GDM who had BMI recorded. The mean BMI was 32.4 (SD \pm 6.8). The lowest BMI recorded was 19.7 kg/m², and the highest was 53.1 kg/m².




BMI: There were 142 patients with GDM who had BMI recorded. Of these, 17 patients (12.0%) had BMI <25 kg/m², 40 patients (28.2%) had a BMI 25-30 kg/m², and 85 patients (59.9%) had a BMI \geq 30 kg/m².




ATSI: There were 161 patients with GDM who had data recorded on whether they identify as Aboriginal/Torres Strait Islander (ATSI). 151 patients (93.8%) did not identify as ATSI. 10 patients (6.2%) did identify as ATSI.




Australian born: There were 160 patients with GDM who had data recorded on country of birth. 111 patients (69.4%) were born in Australia, and 49 patients (30.6%) were born outside of Australia.






NDSS: There were 159 patients with GDM who had data recorded on NDSS registration. 123 patients (77.4%) were registered with NDSS, and 36 patients (22.6%) were not registered with NDSS.






Glucose monitoring: There were 156 patients with GDM who had data recorded on method of blood glucose monitoring. 154 patients (98.7%) used finger prick monitoring, 2 patients (1.3%) did not monitor blood glucose and 0 patients used continuous glucose or flash glucose monitoring.








Smoking status: There were 162 patients with GDM who had data recorded on smoking status. 131 patients (80.9%) had never smoked, and 14 patients (8.6%) were current smokers, and 17 patients (10.5%) were past smokers.




Smoking status: There were 29 patients with GDM who had a history of smoking and had data recorded on duration of smoking. 9 patients (31.0%) had smoked for <5 years, 12 patients (41.4%) had smoked for 5-10 years, 8 patients (27.6%) had smoked for 11-20 years, and 0 patients had smoked for >20 years.




Treatment: There were 163 patients with GDM who had data recorded on type of treatment for diabetes. 71 patients (43.6%) were managed with diet-only, 13 patients (8.0%) were treated with tablets, 75 patients (46.0%) were treated with insulin, 2 patients (1.2%) were treated with insulin and tablets, 1 patient (0.6%) was treated with an injectable, 1 patient (0.6%) was treated with an injectable and insulin, and 0 patients were treated with injectables/tablets or injectables/tablets/insulin.






Insulin mode: There were 78 patients with GDM treated with insulin who had data recorded on modality of insulin delivery. 57 patients (73.1%) were treated with basal insulin, 21 patients (26.9%) were treated with basal-bolus insulin, 2 patients (2.6%) were treated with pre-mixed insulin, and 0 patients were treated with pump-driven insulin (not graphed).




Blood Glucose Control: There were 49 patients with GDM who had HbA_{1c} recorded. Mean HbA_{1c} was 5.3 (SD ± 0.4) %. The lowest HbA_{1c} recorded was 4.4% and the highest was 6.5%.



Urinary albumin: There were 26 patients with GDM who had urinary albumin recorded. 9 patients (34.6%) had normoalbuminuria, 15 patients (57.7%) had microalbuminuria, and 2 patients (7.7%) had macroalbuminuria.



Aspirin: There were 160 patients with GDM who had aspirin use recorded. 22 patients (13.8%) were taking aspirin, 137 patients (85.6%) were not taking aspirin, and aspirin was contraindicated in 1 patient (0.6%).



7. Historical Comparison of Pooled Data - adults

Table 7.1 Demographic data

Category	2021	2019
Number of patients	4484	6116
Age (years) (median (IQR))	60.8 (46.6 - 70.4)	60.3 (46.1 - 70.2)
Median diabetes duration (years) (median (IQR))	14.0 (7 - 22)	14.0 (6 - 21)
Sex (%) (male)	54.5	52.6
Pregnant (%) (females aged 18-55 years)	5.7	6.8
Diabetes type (%)		
T1DM	29.2	28.4
T2DM	67.7	68.0
Don't know	0.6	1.5
Other	2.5	2.1
Unstated	0.4	0.4
Initial visit (%)	14.0	19.7
Aboriginal/Torres Strait Islander (%)	3.5	4.2
DVA patient (%)	1.3	1.2
NDSS member (%)	94.0	94.8

Table 7.2 Overall mean data

Fields	2021 (Mean + SD)	2019 (Mean + SD)
BMI (kg/m ²)	31.5 ± 7.7	31.7 ± 9.5
Systolic BP (mmHg)	132 ± 17	132 ± 17
Diastolic BP (mmHg)	76 ± 11	76 ± 11
	Median (IQR)	Median (IQR)
HbA _{1c} (%)	7.9 (7.0 - 9.2)	7.8 (6.9 - 9)
HbA _{1c} (mmol/mol)	61.0 (51 - 75.0)	62.0 (52 - 75)
Total cholesterol (mmol/L)*	4.1 (3.5 - 5.0)	4.2 (3.5 - 5.0)
HDL cholesterol (mmol/L)*	1.1 (0.92 - 1.4)	1.2 (0.99 - 1.4)
Triglyceride (mmol/L)*	1.6 (1.1 - 2.4)	1.6 (1.1 - 2.3)
LDL cholesterol (mmol/L)*	2.0 (1.5 - 2.8)	2.1 (1.5 - 2.8)

* Irrespective of fasting status

Table 7.3 Complications

Complications	2021 (%)	2019 (%)
Foot ulceration	5.8	5.2
Peripheral vascular disease	7.6	7.7
Peripheral neuropathy	22.3	19.9
Lower limb amputation	1.7	2.8
Microalbuminuria	28.1	27.7
Macroalbuminuria	10.0	11.4
Proteinuria >300mg/24hr	28.6	16.7
eGFR <90 (ml/min/1.73m ²)	59.5	60.8
eGFR <60 (ml/min/1.73m ²)	23.1	24.4

Table 7.4 Risk factor data

Risk factors	2021 (%)	2019 (%)
Current smoker	11.4	12.3
Past smoker	31.9	31.7
On anti-hypertensive therapy	60.4	60.6
On lipid modifying therapy	61.5	58.7
BP >130/80	54.2	54.2
Raised total cholesterol ≥4.0 mmol/L	56.2	58.0
Raised LDL cholesterol ≥2.0 mmol/L	53.0	55.2
Reduced HDL cholesterol <1.0 mmol/L	27.8	25.1
Raised triglycerides ≥2.0 mmol/L	38.1	35.5
Overweight/obese ≥25 kg/m ²	80.7	81.6

Table 7.5 Complication/event in the last 12 months

Complication/event	2021 (%)	2019 (%)
Myocardial infarct	2.9	2.5
CABG/angioplasty/stent	2.7	2.4
Cerebral stroke	1.3	1.5
Congestive cardiac failure	4.4	4.5
End stage renal disease	4.2	4.1
Blindness	1.9	1.4
Sexual dysfunction	12.1	12.1
Severe hypoglycaemia	4.5	5.9

Table 7.6 Complication/event (prior to the last 12 months)

Complication/event	2021 (%)	2019 (%)
Myocardial infarction	10.2	9.6
CABG/angioplasty/stent	10.0	9.9
Cerebral stroke	5.1	4.4
Congestive cardiac failure	4.9	5.3
End stage renal disease	4.5	4.8
Blindness	1.6	1.7
Sexual dysfunction	11.6	11.6
Severe hypoglycaemia	9.0	10.2

Table 7.7 Any complication/event (during or prior to the last 12 months)

Complication/event	2021 (%)	2019 (%)
Myocardial infarction	12.0	10.7
CABG/angioplasty/stent	11.8	11.1
Cerebral stroke	5.9	5.3
Congestive cardiac failure	6.1	6.3
End stage renal disease	4.8	4.8
Blindness	1.4	1.4
Sexual dysfunction	13.2	13.2
Severe hypoglycaemia	11.5	12.2

Table 7.8 Blood glucose control, age, diabetes duration and BMI

Category	2021 Median (IQR)	2019 Median (IQR)
Blood Glucose Control (%)		
Mean HbA _{1c} T1DM	8.0 (7.0 – 9.0)	8.0 (7.0 – 9.0)
Mean HbA _{1c} T2DM	8.0 (7.0 – 9.0)	8.0 (7.0 – 9.0)
Mean HbA _{1c} T2DM diet only	6.0 (6.0 – 7.0)	6.0 (6.0 – 7.0)
Mean HbA _{1c} T2DM tablets only	7.0 (7.0 – 8.0)	7.0 (6.0 – 8.0)
Mean HbA _{1c} T2DM insulin only	8.0 (7.0 – 10.0)	8.0 (7.0 – 9.0)
Mean HbA _{1c} T2DM insulin & tablets	8.0 (8.0 – 10.0)	8.0 (7.0 – 9.0)
Age (years)		
Mean age T1DM	41.0 (28.0 – 58.0)	41.0 (28.0 – 56.0)
Mean age T2DM	65.0 (56.0 – 73.0)	65.0 (56.0 – 73)
Mean age T2DM diet only	68.0 (58.0 – 76.0)	67.0 (56.0 – 77)
Mean age T2DM tablets only	66.0 (56.0 – 74.0)	65.0 (56.0 – 72)
Mean age T2DM insulin only	68.0 (58.0 – 77.0)	68.0 (58.0 – 77)
Mean age T2DM insulin & tablets	66.0 (57.0 – 74.0)	66.0 (57.0 – 73.0)
Duration of diabetes (years)		
Mean duration T1DM	18.0 (10.0 – 30.0)	18.0 (10.0 – 29.0)
Mean duration T2DM	13.0 (6.0 – 21.0)	12.0 (6.0 – 20.0)
Mean duration T2DM diet only	4.0 (1.0 – 10.0)	5.0 (1.0 – 10.0)
Mean duration T2DM tablets only	9.0 (3.0 – 16.0)	8.0 (3.0 – 14.0)
Mean duration T2DM insulin only	20.0 (11.0 – 26.0)	17.0 (10.0 – 24.0)
Mean duration T2DM insulin & tablets	17.0 (10.0 – 23.0)	16.0 (10.0 – 22.0)

BMI (kg/m ²)	2021	2019
	(Mean + SD)	(Mean + SD)
Mean BMI T1DM	26.6 ± 5.3	26.6 ± 5.3
Mean BMI T2DM	32.6 ± 7.2	32.6 ± 7.2
Mean BMI T2DM diet only	32.4 ± 7.1	31.3 ± 6.4
Mean BMI T2DM tablets only	33.5 ± 7.9	33.6 ± 8.3
Mean BMI T2DM insulin only	33.8 ± 8.0	33.7 ± 7.9
Mean BMI T2DM insulin & tablets	34.2 ± 8.0	34.1 ± 8.0

Table 7.9 Treatment of cardiovascular risk factors

Treatment	2021 (%)	2019 (%)
On anti-hypertensive therapy	60.4	60.6
On lipid modifying therapy	61.5	58.7
On anti-platelet therapy	30.5	30.5

Participating sites were asked to complete a questionnaire at the completion of the data collection phase, to assess the participating sites' satisfaction with the overall process of data collection. Free text responses to questions were reviewed individually and utilised to refine the data collection instrument and reporting process to assist in running future audits.

Table 7.10 shows the results of the feedback (the Likert Scale responses) from participating sites to the specific questions related to the data collection. The results improved in 2021 compared to previous years. However, the ease and time needed to complete the data collection form remains of concern to participating sites.

Table 7.10 Post Data Collection Questionnaire Results

Questionnaire category	Likert Scale: 1 = Poor, 3 = Midpoint, 5 = Good			
	2021 (n=25) (Mean + SD)	2019 (n=68) (Mean + SD)	2017 (n=43) (Mean + SD)	2015 (n=37) (Mean + SD)
Information package/letters	4.6 ± 0.6	4.4 ± 0.7	4.1 ± 0.7	4.3 ± 0.7
Data definitions form	4.6 ± 0.6	4.3 ± 0.7	4.0 ± 0.8	4.0 ± 0.7
Format (layout of data items)	4.2 ± 0.7	4.0 ± 1.0	3.7 ± 1.0	3.8 ± 0.9
Ease of form completion	4.1 ± 0.7	3.7 ± 1.0	3.4 ± 1.2	3.7 ± 1.1
Time to complete the form	3.7 ± 1.1	3.1 ± 1.1	2.6 ± 1.7	3.1 ± 1.0

The results in Table 7.11, from 25 respondents (one site provided data through in-house data extraction, data not shown), showed that there was general approval of the 'Process' including the information provided, data definitions form and overall format. These findings showed improvement compared to 2019 in both paper-based and web-based data collections.

Table 7.11 Post Data Collection Questionnaire – Response by data collection method

Questionnaire category	Likert Scale 1= Poor, 3= Midpoint, 5= Good			
	Paper-based (Mean ± SD)		Web-based (Mean ± SD)	
	2021 (n=14)	2019 (n=46)	2021 (n=10)	2019 (n=20)
Information package/letters	4.7 ± 0.5	4.5 ± 0.7	4.5 ± 0.7	4.2 ± 0.7
Data Definitions form	4.7 ± 0.5	4.5 ± 0.7	4.4 ± 0.7	4.1 ± 0.7
Format (layout of data items)	4.1 ± 0.8	4.1 ± 0.8	4.1 ± 0.6	4.0 ± 0.9
Ease of completion	3.9 ± 0.7	3.6 ± 0.9	4.3 ± 0.7	3.9 ± 0.9
Time to complete the form	3.9 ± 0.9	3.1 ± 1.1	3.5 ± 1.3	3.2 ± 1.0

Diabetes Publications & Resource List 2020

There are many resources available nationally that provide evidence-based guidelines on how care should be provided and what outcomes should be achieved for people living with diabetes.

The following is a list of commonly used resources in Australia. The list also includes health care organisations involved in the provision of diabetes care. These links have been divided into topics. Please click on the topic of interest.

Contents

Prevention, Prediabetes & Diagnostics	2
Hospital Guidelines	2
Obesity Management	2
Type 1 Diabetes	3
Type 2 Diabetes	3
Elderly / Aged Care / End of Life	4
Consulting / Diabetes Education	5
Renal Information	5
Foot Care	5
Eye Care	6
Diabetes Educators	6
fact Sheets/Patient Resources	7
Nutrition / Diet	7
Pregnancy	8
Aboriginal and Torres Strait Islander	9
CALD / Multilingual	9
Data / Research / Quality Improvement	10
HbA1c	11
Subcutaneous Devices / Techniques	11
Driving	12
Workplace	13
NDSS	14
Diabetes Related Organisations In Australia	14
Australian Government Departments	14
Professional Associations & Organisations	14
International Diabetes Associations	14
Support	15

Title	Description / Link
Prevention, Prediabetes & Diagnostics	
National Evidence Based Guideline for Case Detection and Diagnosis of Type 2 Diabetes	https://nadc.net.au/wp-content/uploads/2019/08/National-Evidence-Based-Guideline-for-Case-Detection-and-Diagnosis-of-Type-2-Diabetes.pdf
National Evidence Based Guideline for the Primary Prevention of Type 2 Diabetes	https://nadc.net.au/wp-content/uploads/2019/08/National-Evidence-Based-Guidelines-for-the-Primary-Prevention-of-Type-2-Diabetes.pdf
The Australian Diabetes Educators Association (ADEA) and the Australian Diabetes Society (ADS) Position Statement on Prediabetes	https://nadc.net.au/wp-content/uploads/2019/08/The-Australian-Diabetes-Educators-Association-ADEA-and-the-Australian-Diabetes-Society-ADS-Position-Statement-on-pre-diabetes.pdf
Australian Diabetes Society Position Statement: The Prevention and Management of Type 2 Diabetes in the Context of Psychotic Disorders	https://diabetessociety.com.au/documents/ADS_Mental_Health_and_Type_2D_Position_Statement2017.pdf
Life! Program	<p>The Life! program is a free Victorian lifestyle modification program aimed at type 2 diabetes and cardiovascular disease risk reduction. Run by expert health professionals, the program is delivered as a group course or a telephone health coaching service.</p> <p>https://www.lifeprogram.org.au/</p>
Hospital Guidelines	
ADS Guidelines for Routine Glucose Control in Hospital	http://diabetessociety.com.au/documents/ADSGuidelinesforRoutineGlucoseControlinHospitalFinal2012.pdf
ADS Peri-Operative Diabetes Management Guidelines	<p>These guidelines are primarily intended to provide assistance for those practitioners whose primary focus is not diabetes or who do not have the support of local diabetes expertise in their management of patients with diabetes undergoing surgical procedures.</p> <p>http://diabetessociety.com.au/documents/PerioperativeDiabetesManagementGuidelinesFINALCleanJuly2012.pdf</p>
Obesity Management	
Australian Obesity Management Algorithm	<p>This statement has been developed by a working group with representatives from the Australian Diabetes Society, the Australian and New Zealand Obesity Society and the Obesity Surgery Society of Australian and New Zealand.</p> <p>The aims of the document are to:</p> <ol style="list-style-type: none"> 1) Assist general practitioners (GPs) in treatment decisions for non-pregnant adults with obesity 2) Provide a practical clinical tool to guide the implementation of existing guidelines for the treatment of obesity in the primary care setting in Australia. <p>https://diabetessociety.com.au/documents/ObesityManagementAlgorithm18.10.2016FINAL.pdf</p>

<p>Metabolic Surgery in the Treatment Algorithm for Type 2 Diabetes: A Joint Statement by International Diabetes Organizations</p>	<p>The ADS has recently endorsed international guidelines that recommend metabolic surgery for patients with type 2 diabetes and class III (BMI ≥ 40 kg/m²) obesity and patients with type 2 diabetes with class II (BMI 35.0–39.9 kg/m²) obesity who have had inadequate glycaemic control with lifestyle and pharmacotherapy.</p> <p>https://diabetessociety.com.au/documents/RubinoetalDiabetesCare2016.pdf</p>
<p>Type 1 Diabetes</p>	
<p>Alcohol and type 1 diabetes</p>	<p>https://static.diabetesaustralia.com.au/s/fileassets/diabetes-australia/a956cdaa-b77c-466e-9772-f265ec83183f.pdf</p>
<p>Diabetes in Pregnancy booklet for women with type 1 – Having a Healthy Baby</p>	<p>https://nadc.net.au/wp-content/uploads/2019/08/Diabetes-in-Pregnancy-booklet-for-women-with-type-1-%E2%80%93-Having-a-Healthy-Baby.pdf</p>
<p>Drug use and type 1 diabetes</p>	<p>https://static.diabetesaustralia.com.au/s/fileassets/diabetes-australia/00c929cf-b50b-4ef4-8792-8d12ac488af2.pdf</p>
<p>Guidelines for Sick Day Management for People with Diabetes</p>	<p>Provides readily accessible information recommending strategies for managing sick days in diabetes. To view the technical document for health professional:</p> <p>https://nadc.net.au/wp-content/uploads/2019/08/Guidelines-for-Sick-Day-Management-for-People-with-Type-1-and-2-Diabetes.pdf</p> <p>To view the sick day management of adults with type 1 diabetes consumer resources:</p> <p>https://nadc.net.au/wp-content/uploads/2019/08/Guidelines-for-Sick-Day-Management-for-People-with-Type-1.pdf</p>
<p>NDSS Pregnancy and Diabetes Website</p>	<p>Information for women with type 1 or type diabetes planning a pregnancy now or in the future</p> <p>https://www.ndss.com.au/about-diabetes/pregnancy/</p>
<p>National Evidence Based Clinical Care Guidelines for Type 1 Diabetes in Children, Adolescents and Adults</p>	<p>http://diabetessociety.com.au/downloads/Type1guidelines14Nov2011000.pdf</p>
<p>Travelling and type 1 diabetes</p>	<p>https://static.diabetesaustralia.com.au/s/fileassets/diabetes-australia/2e44a739-242e-4a2e-97d0-3874359b907c.pdf</p>
<p>Understanding Hypoglycaemia</p>	<p>The International Hypoglycaemia Study Group (IHSG) has launched a website providing information about hypoglycaemia in diabetes. It includes statements and guidelines, practice tools for health professionals and much more.</p> <p>https://ihsgonline.com/</p>
<p>Type 2 Diabetes</p>	
<p>ADS Position Statement on A New Blood Glucose Management Algorithm for Type 2 Diabetes</p>	<p>This position statement developed by the Australian Diabetes Society outlines the risks, benefits and costs of the available therapies and suggests a treatment algorithm incorporating the older and newer agents. Summary of this ADS Position Statement is as follows:</p> <p>To read or download the full version of the ADS A New Blood Glucose Management Algorithm for Type 2 Diabetes Position Statement (Updated: December, 2016)</p>

	https://diabetessociety.com.au/documents/ADS_POSITIONSTATEMENT_v2.4.pdf
T2D Treatment Website (A New Blood Glucose Management Algorithm for Type 2 Diabetes)	<p>The blood glucose management algorithm for type 2 diabetes outlines the risks, benefits and costs of available therapies and provides an approach for how to incorporate older and newer agents. To view the algorithm and associated resources:</p> <p>http://t2d.diabetessociety.com.au/</p>
Diabetes Management in General Practice 2016/18	<p>General practitioners continue to provide most of the medical support to people with type 2 diabetes. This guide plays an important role in providing a readable summary of current guidelines and recommendations from various sources on the management of type 2 diabetes in the general practice setting.</p> <p>https://static.diabetesaustralia.com.au/s/fileassets/diabetes-australia/5d3298b2-abf3-487e-9d5e-0558566fc242.pdf</p>
Australian Diabetes Society Position Statement: The Prevention and Management of Type 2 Diabetes in the Context of Psychotic Disorders	<p>To read or download your copy, please click here</p> <p>https://nadc.net.au/wp-content/uploads/2019/08/Australian-Diabetes-Society-Position-Statement-The-Prevention-and-Management-of-Type-2-Diabetes-in-the-Context-of-Psychotic-Disorders-1.pdf</p>
National Evidence Based Guideline for Diagnosis, Prevention and Management of Chronic Kidney Disease in Type 2 Diabetes	http://static.diabetesaustralia.com.au/s/fileassets/diabetes-australia/14d82dbb-d776-40c5-a848-9b22f251514e.pdf
Elderly / Aged Care / End of Life	
Glucose Lowering Medicines and Older People with Diabetes: Information for Personal Care Workers	<p>This is the links to the Q-Med project resources which are available on the Australian Disease Management Association (ADMA) Online Clearinghouse site.</p> <p>https://nadc.net.au/wp-content/uploads/2019/08/GLM-PCW.pdf</p>
Glucose Lowering Medicines and Older People with Diabetes: Information for Registered and Enrolled Nurses	<p>This is the links to the Q-Med project resources which are available on the Australian Disease Management Association (ADMA) Online Clearinghouse site.</p> <p>https://nadc.net.au/wp-content/uploads/2019/08/GLM-Nurses.pdf</p>
Glucose Lowering Medicines: Information for Older People with Diabetes and their Family Members	<p>This is the links to the Q-Med project resources which are available on the Australian Disease Management Association (ADMA) Online Clearinghouse site.</p> <p>https://nadc.net.au/wp-content/uploads/2019/08/GLM-PWD.pdf</p>
Aged Care Diabetes Care Checklist	<p>This is a checklist to assist in the management of diabetes care for the aged.</p> <p>https://static.diabetesaustralia.com.au/s/fileassets/diabetes-australia/81e7639f-0d20-4461-b0c8-c3be51cbe7ce.pdf</p>
Diabetes Management in Aged Care: A practical handbook	<p>This is an updated version of the resource developed in 2012 and is aimed at care staff.</p> <p>https://static.diabetesaustralia.com.au/s/fileassets/diabetes-australia/ae2124a0-5695-4adf-ba27-f5408b19089d.pdf</p>
Diabetes Management in Aged Care: Fact sheets for care workers	<p>The diabetes management in aged care fast facts for care workers is a booklet of quick reference sheets that aim to give care staff basic</p>

	<p>information on how to manage diabetes in a residential care setting: To read or download your copy of the E-book:</p> <p>https://static.diabetesaustralia.com.au/s/fileassets/diabetes-australia/f49f1343-e606-4dad-ac63-16bcced3a313.pdf</p>
Guidelines for Managing Diabetes at the End of Life	<p>These guidelines were developed in 2014 to assist with the management of Diabetes at the End of Life. To access these guidelines, search for these on the ADMA website.</p> <p>https://adma.org.au/</p>
Older People – Healthy Eating Guide	https://static.diabetesaustralia.com.au/s/fileassets/diabetes-australia/1581db13-3932-40fe-a46b-fcd719c60bdf.pdf
Older People – Managing Diabetes as You Age	https://www.ndss.com.au/wp-content/uploads/resources/booklet-managing-diabetes-as-you-age-guide-for-people-over-65.pdf
Older People – You and your Health Care Team	https://www.ndss.com.au/wp-content/uploads/resources/booklet-your-health-care-team-guide-for-people-over-65.pdf
The McKellar guidelines for Managing Older people with Diabetes in Residential and Other Care Settings	<p>These Guidelines were developed in 2014 to assist with the management of Diabetes in Residential Care Facilities. To access these guidelines, search for these on the ADMA website.</p> <p>https://nadc.net.au/wp-content/uploads/2019/08/The-McKellar-Guidelines-for-Managing-Older-People-with-Diabetes-in-Residential-and-Other-Care-Settings_v3_e.pdf</p>
Consulting / Diabetes Education	
A new language for diabetes – Improving communications with and about people with diabetes	<p>Diabetes Australia has released an updated version (May 2016) of their position statement on language around diabetes.</p> <p>https://static.diabetesaustralia.com.au/s/fileassets/diabetes-australia/f4346fcb-511d-4500-9cd1-8a13068d5260.pdf</p>
The use of Language in Diabetes Care and Education	<p>Article from The American Association of Diabetes Educators (AADE) and American Diabetes Association on the use of language in Diabetes Care and Education.</p> <p>https://nadc.net.au/wp-content/uploads/2019/08/The-use-of-Language-in-Diabetes-Care-and-Education.pdf</p>
Enhancing your consulting skills	<p>“Enhancing Your Consulting Skills” was developed by the ADS for the NDSS. It is now available in electronic format through the ADS website. It can be downloaded free of charge for individual use. Please note that you will be required to submit a request for download and obtain your password prior to receiving the download link. Hard copies of the resource are available from the ADS Secretariat.</p> <p>http://diabetessociety.com.au/download-request.asp</p>
National Evidenced Based Guideline for Patient Education in Type 2 Diabetes	<p>This document provides minimum standards for development and facilitation of diabetes education programs.</p> <p>http://static.diabetesaustralia.com.au/s/fileassets/diabetes-australia/b9b8789d-c7ba-473d-bd49-0b7d793a0835.pdf</p>
Outcomes and Indicators for Diabetes Education: National Consensus Position Information and	<p>This report details a systematically derived framework of nationally agreed goals, outcomes and indicators for diabetes education. It</p>

Education for People with Diabetes: a ‘Best Practice’ Strategy	<p>provides a benchmark and policy platform for refining and evaluating the consistency, quality and effectiveness of diabetes education services which can be applied nationally and/or at a regional or local service level.</p> <p>https://static.diabetesaustralia.com.au/s/fileassets/diabetes-australia/281a322b-44df-43f8-b407-39dca2136011.pdf</p>
Renal Information	
National Evidence Based Guideline for Diagnosis, Prevention and Management of Chronic Kidney Disease in Type 2 Diabetes	<p>http://static.diabetesaustralia.com.au/s/fileassets/diabetes-australia/14d82dbb-d776-40c5-a848-9b22f251514e.pdf</p>
Foot Care	
<ul style="list-style-type: none"> • Australasian Podiatry Council • Limbs 4 Life • Diabetic Foot Australia 	
National Evidence Based Guidelines on Prevention, Identification and Management of Foot Complications in Diabetes	<p>Approved by the NHMRC, the full guideline, clinical guide, consumer guides and technical report can be downloaded:</p> <p>https://nadc.net.au/wp-content/uploads/2019/08/National-Evidence-Based-Guidelines-on-Prevention-Identification-and-Management-of-Foot-Complications-in-Diabetes.pdf</p>
Standards for High Risk Foot Services (HRFS) in NSW	<p>To view or download your copy, please TBA</p>
Promoting Optimal Diabetes Foot Care	<p>“Promoting Optimal Diabetes Foot Care” is a set of audio-visual resources based on national and international guidelines. The resources have been designed to help health professionals develop the clinical skills required to deliver high quality foot care to people with diabetes. The set is comprised of three learning modules:</p> <ol style="list-style-type: none"> 1. The Foot Examination https://diabetessociety.com.au/diabetesfoot/the-foot-examination-submit-request.asp 2. Preventative Foot Care https://diabetessociety.com.au/diabetesfoot/preventative-foot-care-submit-request.asp 3. Managing basic diabetes foot complications https://diabetessociety.com.au/diabetesfoot/managing-foot-complications-submit-request.asp
Wound Institute of Australia	<p>The Wound Healing Institute of Australia has developed a comprehensive set of modules on wound care, including specific modules on foot ulcers and leg ulcers.</p> <p>Find out more about these modules at: https://www.whia.com.au/product-category/online-learning/</p>
NADC Foot Network	<p>2017 ASM Presentation by Stephen Twigg and Leanne Mullan – Slides can be viewed (part 1) and (part 2)</p>

	<p>https://nadc.net.au/wp-content/uploads/2020/01/ASM-Meet-the-expert-Twigg-Mullan-2017-Part-1.pdf</p> <p>https://nadc.net.au/wp-content/uploads/2020/01/ASM-Meet-the-expert-Twigg-Mullan-2017-Part-2.pdf</p>
Eye Care	
	<ul style="list-style-type: none"> • Optometrists Association of Australia
Diabetes Educators	
National Core Competencies for Credentialed Diabetes Educators	<p>Provides a reference and a framework for guiding policy on the training and credentialing of diabetes educators.</p> <p>https://nadc.net.au/wp-content/uploads/2019/08/National-Core-Competencies-for-Credentialed-Diabetes-Educators.pdf</p>
National Standards of Practice for Diabetes Educators	<p>One of the strategies developed by ADEA to promote a quality professional diabetes education practice.</p> <p>https://nadc.net.au/wp-content/uploads/2019/08/National-Standards-of-Practice-for-Diabetes-Educators.pdf</p>
The Role of Credentialed Diabetes Educators and Accredited Practising Dietitians in the Delivery of Diabetes Self-Management and Nutrition Services for People with Diabetes	<p>https://nadc.net.au/wp-content/uploads/2019/08/The-Credentialed-Diabetes-Educator-in-Australia-%E2%80%93-Role-and-Scope-of-Practice.pdf</p>
Fact Sheets / Patient Resources	
Baker IDI Fact Sheets	<p>These materials have been developed by Baker IDI experts for use by clients and health professionals for patient education. The Institute is committed to providing credible, evidence-based health information regarding optimum approaches to the prevention and management of disease.</p> <p>https://www.bakeridi.edu.au/health-hub/fact-sheets</p>
Diabetes Australia patient information and resources	<p>https://www.diabetesaustralia.com.au/</p>
National Diabetes Services Scheme (NDSS) resources including fact sheets	<p>35 facts sheets including those in other languages are available through the NDSS website.</p> <p>https://www.ndss.com.au/about-diabetes/resources/</p>
Diabetes and Emotional Health Handbook and Toolkit	<p>‘Diabetes and Emotional Health’ is a handbook and toolkit developed as part of the National Diabetes Services Scheme Mental Health and Diabetes National Development Programme. The handbook has been designed as an evidence-based, practical resource to enable health professionals to identify, address, and communicate about emotional problems during consultations with adults with diabetes. A related toolkit contains resources to complement the handbook, including summary cards of several chapters, questionnaires for routine clinical use, and related ‘factsheets’ for people with diabetes. The latter provide information about the psychological topics covered in the chapters of the handbook, tips about what people with diabetes can do when they experience this problem and where they can get further support. Both the handbook and the toolkit can be accessed electronically via the Health Professionals tab of the NDSS website</p>

	<p>(ndss.com.au). The direct link is www.ndss.com.au/online-resources-for-health-professionals (you will need to 'sign up' to view it). The 'factsheets' are also available directly to people with diabetes electronically via the NDSS website. The direct link is https://www.ndss.com.au/diabetes-and-emotional-health.</p>
<p>Nutrition / Diet</p>	
<ul style="list-style-type: none"> • Dietitians Association of Australia (DAA) • Food Standards Australia New Zealand (FSANZ) • Glycemic Index Ltd • Nutrition Australia • Coeliac Australia • Diabetes Australia recipes 	
<p>Healthy Eating Guide for Older Australians with Diabetes</p>	<p>https://www.ndss.com.au/wp-content/uploads/resources/booklet-healthy-eating-guide-for-people-over-65.pdf</p>
<p>Diabetes and Ramadan</p>	<p>To assist health professionals, religious leaders and people with diabetes who fast during Ramadan, the Australian Diabetes Society, in conjunction with the International Diabetes Federation and Diabetes and Ramadan International Alliance, has endorsed the following brochures:</p> <ul style="list-style-type: none"> • Diabetes during Ramadan: Patient Guide <p>https://nadc.net.au/wp-content/uploads/2019/08/Diabetes-during-Ramadan-Patient-Guide.pdf</p> <ul style="list-style-type: none"> • Ramadan and Diabetes: Guidance Sheet for Imam <p>https://nadc.net.au/wp-content/uploads/2019/08/Ramadan-and-Diabetes-Guidance-Sheet-for-Imam.pdf</p> <ul style="list-style-type: none"> • Management of Diabetes During Ramadan: Quick Reference Guide for Health Professionals <p>https://nadc.net.au/wp-content/uploads/2019/08/Management-of-Diabetes-During-Ramadan-Quick-Reference-Guide-for-Health-Professionals.pdf</p> <p>In February 2017 the NADC joined representatives from the ADS and the Diabetes and Ramadan (DaR) International Alliance at the first-ever Diabetes and Ramadan Symposium at Concord Repatriation General Hospital. The event promoted the new IDF-DaR Diabetes and Ramadan Practical Guidelines, which aim to support healthcare professionals to better support patients during this important religious period.</p> <p>A copy of the guidelines can be downloaded from the IDF website at http://www.idf.org/guidelines/diabetes-in-ramadan and presentations from the event can be viewed here: http://nadc.net.au/video/</p> <p>or via the NADC YouTube channel - NADC Australia.</p> <p>Diabetes and Ramadan Overview</p> <ul style="list-style-type: none"> • https://www.youtube.com/watch?v=9Cil643q8UQ&t=43s <p>Diabetes and Ramadan Symposium Introduction - Dr Sof Andrikopoulos</p>

	<ul style="list-style-type: none"> • https://www.youtube.com/watch?v=ZuSSCI3OIGU Diabetes and Ramadan Dr Marwan Obaid • https://www.youtube.com/watch?v=3lX6hd2sy6w&t=179s Diabetes and Ramadan 2 Case Studies Dr Elif Ekinci • https://www.youtube.com/watch?v=VTPkSquM3cA&t=19s Ramadan, Diabetes and Pregnancy Dr Sarah Abdo • https://www.youtube.com/watch?v=GjCUBkErI6g IDF DAR Practical Guidelines Dr Mohamed Hassanein • https://www.youtube.com/watch?v=2NUF0sVrYaw&t=83s
Pregnancy	
	<ul style="list-style-type: none"> • The Australasian Diabetes in Pregnancy Society (ADIPS) https://www.adips.org/Index.asp • Pregnancy and Diabetes http://pregnancyanddiabetes.com.au/
Diabetes in Pregnancy booklet for women with type 1 – Having a Healthy Baby	https://www.ndss.com.au/wp-content/uploads/resources/booklet-pregnancy-having-healthy-baby-type1.pdf
Diabetes in Pregnancy booklet for women with type 2 – Having a Healthy Baby	http://www.pregnancyanddiabetes.com.au/globalassets/pdfs/pregnancy_having-healthy-baby-t2-booklet_aug15.pdf
Gestational Diabetes - Caring for Yourself and Your Baby	https://www.ndss.com.au/wp-content/uploads/resources/booklet-gestational-diabetes-caring-for-yourself-and-baby.pdf
Life after Gestational Diabetes	https://www.ndss.com.au/wp-content/uploads/resources/booklet-gestational-diabetes-life-after.pdf
NDSS Understanding Gestational Diabetes Factsheet	<p>https://static.diabetesaustralia.com.au/s/fileassets/diabetes-australia/86373a1a-2f2f-4f73-a872-7f9f3a45b1cf.pdf</p> <p>Also available in 10 different languages, to view or download translated factsheets:</p> <p>https://www.ndss.com.au/about-diabetes/information-in-your-language/</p>
NDSS Pregnancy Planning Checklist	http://www.pregnancyanddiabetes.com.au/static/assets/staticchecklist.pdf
NDSS Pregnancy and Diabetes Factsheet	<p>To view or download your copy, please click here</p> <p>https://www.ndss.com.au/wp-content/uploads/fact-sheets/fact-sheet-pregnancy-and-diabetes.pdf</p> <p>Also available in 10 different languages, to view or download translated factsheets:</p> <p>https://www.ndss.com.au/about-diabetes/information-in-your-language/</p>

Aboriginal and Torres Strait Islander	
<ul style="list-style-type: none"> • HealthInfoNet 	
Aboriginal and Torres Strait Islander Resources – NDSS	https://www.ndss.com.au/living-with-diabetes/about-you/aboriginal-and-torres-strait-islander-peoples/resources/
Aboriginal and Torres Strait Islander Resources – Diabetes Australia State Branches	<p>Diabetes Victoria - https://www.diabetesvic.org.au/ATSI-resources</p> <p>Diabetes Queensland - https://www.diabetesqld.org.au/managing-diabetes/aboriginal-and-torres-strait-islander.aspx https://www.diabetesqld.org.au/managing-diabetes/aboriginal-and-torres-strait-islander/diabetes-and-me.aspx</p> <p>Diabetes Western Australia - https://diabeteswa.com.au/manage-your-diabetes/resources/aboriginal-health-resources/</p> <p>Diabetes Tasmania - https://www.diabetestas.org.au/News-and-Resources/Resources/Aboriginal-and-Torres-Strait-Islander-NDSS-Resources</p> <p>Diabetes NSW and ACT - https://diabetesnsw.com.au/useful-tools/information-sheets/indigenous-information-sheets/</p> <p>Feltman Training - https://www.youtube.com/watch?v=eRIfsTqD7QM&t=327s https://www.diabetesvic.org.au/ATSI-resources</p>
Online Diabetes Education Training Manual for Aboriginal Health Workers	<p>An online training manual has been developed to increase diabetes knowledge among Aboriginal Health Workers to better support Aboriginal and Torres Strait Islander peoples with diabetes and assist them in self-managing their diabetes.</p> <p>This training is targeted to Aboriginal and Torres Strait Islander Health Practitioners and Aboriginal and Torres Strait Islander Health Workers who have completed a minimum of Certificate IV in Aboriginal and/or Torres Strait Islander Primary Health Care (Community Care) or (Practice).</p> <p>This course is available through the ADEA Learning Management System at: learning.adea.com.au</p> <p>https://learning.adea.com.au/lms/login/index.php</p>
Your guide to Medicare for Indigenous health services	<p>The department of Human Services have updated the newly launched education resource, <i>“Your guide to Medicare for Indigenous health services”</i> to incorporate the important 1 July 2018 Medicare changes.</p> <p>To find more Indigenous health education resources please visit Human Services.</p>

CALD / Multilingual

- [Health Translations](#) by the Victorian Government includes translated health information

Web portal for information about diabetes for people from culturally and linguistically diverse backgrounds

To view or download your copy, please [click here](#)
<https://www.ndss.com.au/about-diabetes/information-in-your-language/>

Diabetes and Ramadan

To assist health professionals, religious leaders and people with diabetes who fast during Ramadan, the Australian Diabetes Society, in conjunction with the International Diabetes Federation and Diabetes and Ramadan International Alliance, has endorsed the following brochures:

- [Diabetes during Ramadan: Patient Guide](#)<https://nadc.net.au/wp-content/uploads/2019/08/Diabetes-during-Ramadan-Patient-Guide.pdf>
- [Ramadan and Diabetes: Guidance Sheet for Imam](#)
<https://nadc.net.au/wp-content/uploads/2019/08/Ramadan-and-Diabetes-Guidance-Sheet-for-Imam.pdf>
- [Management of Diabetes During Ramadan: Quick Reference Guide for Health Professionals](#)
<https://nadc.net.au/wp-content/uploads/2019/08/Management-of-Diabetes-During-Ramadan-Quick-Reference-Guide-for-Health-Professionals.pdf>

In February 2017 the NADC joined representatives from the ADS and the Diabetes and Ramadan (DaR) International Alliance at the first-ever Diabetes and Ramadan Symposium at Concord Repatriation General Hospital. The event promoted the new IDF-DaR Diabetes and Ramadan Practical Guidelines, which aim to support healthcare professionals to better support patients during this important religious period.

A copy of the guidelines can be downloaded from the IDF website at <http://www.idf.org/guidelines/diabetes-in-ramadan> and presentations from the event can be viewed here: <http://nadc.net.au/video/>

or via the NADC YouTube channel - [NADC Australia](#).

[Diabetes and Ramadan Overview](#)

- <https://www.youtube.com/watch?v=9Cil643q8UQ&t=43s>

[Diabetes and Ramadan Symposium Introduction - Dr Sof Andrikopoulos](#)

- <https://www.youtube.com/watch?v=ZuSSCI3OIGU>

[Diabetes and Ramadan Dr Marwan Obaid](#)

- <https://www.youtube.com/watch?v=3lX6hd2sy6w&t=179s>

[Diabetes and Ramadan 2 Case Studies Dr Elif Ekinci](#)

- <https://www.youtube.com/watch?v=VTPkSqum3cA&t=19s>

[Ramadan, Diabetes and Pregnancy Dr Sarah Abdo](#)

- <https://www.youtube.com/watch?v=GiCUBkErI6g>

[IDF DAR Practical Guidelines Dr Mohamed Hassanein](#)

- <https://www.youtube.com/watch?v=2NUF0sVrYaw&t=83s>

Data / Research / Quality Improvement	
<ul style="list-style-type: none"> • Diabetes Australia Research Program https://www.diabetesaustralia.com.au/diabetes-australia-research-program • Juvenile Diabetes Research Foundation (JDRF) https://jdrf.org.au/ • The Australian Centre for Behavioural Research in Diabetes https://acbrd.org.au/ • The Diabetes Research Foundation Western Australia http://www.diabetesresearchfoundation.asn.au/ • The John Curtin School of Medical Research https://jcsmr.anu.edu.au/ • The NHMRC Centre of Clinical Research Excellence on Clinical Science in Diabetes (Diabetes CCRE) http://research.unimelb.edu.au/work-with-us/funding/nhmrc/cre • Baker IDI https://www.baker.edu.au/ • The Walter and Eliza Hall Institute of Medical Research https://www.wehi.edu.au/ 	
Australian National Diabetes Audit (ANDA) reports	<p>The primary aim of ANDA is to:</p> <ul style="list-style-type: none"> ·conduct a survey that will assess a standardised set of predefined clinical (AQCA) and self-management diabetes (AQSMa) indicators including demographic and biological variables, and clinical outcomes; ·enable diabetes services to benchmark their practice processes and clinical outcome data against that of other centres; ·enable diabetes services to compare their practice processes and clinical outcome data over time (where participation in previous collections has occurred); and ·provide pooled national data and data grouped by state and metropolitan/regional/remote location on the clinical status of people with diabetes attending diabetes services. <p>This important quality assurance activity promotes continuous improvement in the standard of service provided by diabetes centres and is the primary quality assurance activity of the NADC. To view this data please click here</p> <p>https://nadc.net.au/anda/</p>
ANDA: Lessons from the 2016 Quality Self-Management Audit	<p>ASM 2017 Presentation Slides by Anthony Pease can be accessed here</p> <p>https://nadc.net.au/wp-content/uploads/2019/08/ANDA-2016-at-ADS-2017-1.pdf</p>
NDSS Diabetes Data Snapshots	<p>NDSS national diabetes data snapshots are updated every three months, and provide key statistics for all types of diabetes, type 1 diabetes, type 2 diabetes, gestational diabetes, and insulin therapy. To view or download these snapshots, please click here</p>
Diabetes Map Australia	<p>The Australian Diabetes Map is the only national map monitoring the prevalence of diabetes in Australia.</p> <p>The data contained in the Australian Diabetes Map is derived from the National Diabetes Services Scheme (NDSS) Registrant database* and the Australian Bureau of Statistics (ABS) and shows people diagnosed with diabetes that are registered on the Scheme.</p> <p>It shows the numbers of people diagnosed with diabetes in all parts of Australia with information on age, gender, type of diabetes, ATSI status</p>

	<p>and socio-economic disadvantage. To view the Australian Diabetes Map, please click here</p> <p>https://map.ndss.com.au/#/</p>
2015 Miles Youth Report	<p>To view or download your copy, please click here</p> <p>https://www.ndss.com.au/wp-content/uploads/resources/report-miles-youth-2015.pdf</p>
HbA1c	
Individualisation of HbA1c targets for Adults with Diabetes Mellitus.	<p>To view or download the full version of this guideline, please click here</p> <p>https://diabetessociety.com.au/documents/HbA1cImplementationv423122014LongVersion.pdf</p> <p>To view or download the short version, please click here</p> <p>https://diabetessociety.com.au/documents/HbA1cPressReleaseADS-July2015.pdf</p>
Subcutaneous Devices / Techniques	
ADEA Clinical Guiding Principles for Subcutaneous Injection Technique	<p>The ADEA Clinical Guiding Principles for Subcutaneous Injection Technique identifies a number of broad clinical issues including optimal needle length and angle of needle insertion for children/adolescents and adults of varying anatomical size. These clinical recommendations reinforce the importance of documenting the process of teaching and reviewing injection technique. To view or download your copy, please</p> <p>Page 38</p> <p>https://ade.adea.com.au/wp-content/uploads/2017/09/ADE-September-2017-final2.pdf</p> <p>https://ade.adea.com.au/?s=Subcutaneous+injection+technique%3A+an+update+on+the+Australian+guidelines+and+current+evidence&category_name</p>
Australian New Zealand (ANZ) Forum for Injection Technique & Therapy Expert Recommendations (FITTER)	<p>ANZ FITTER Speaker Presentation Slides:</p> <p>Introduction to FITTER Presentation – Prof Glen Maberly</p> <ul style="list-style-type: none"> • https://nadc.net.au/wp-content/uploads/2020/01/Introduction-to-FITTER-Presentation-Prof-Glen-Maberly.pdf <p>IT in Adults & AU ITQ Findings – Michelle Robins</p> <ul style="list-style-type: none"> • https://nadc.net.au/wp-content/uploads/2020/01/IT-in-Adults-AU-ITQ-Findings-Michelle-Robins.pdf <p>IT In Children – Prof Paul Hofman</p> <ul style="list-style-type: none"> • https://nadc.net.au/wp-content/uploads/2020/01/IT-In-Children-Prof-Paul-Hofman.pdf <p>NZ Perspective & IT Trends – Dr Helen Snell & Dr Brandon Orr-Walker</p>

	<ul style="list-style-type: none"> • https://nadc.net.au/wp-content/uploads/2020/01/NZ-Perspective-IT-Trends-Dr-Helen-Snell-Dr-Brandon-Orr-Walker.pdf <p>The Role of General Prac in IT Education for Patients – Dr Kean-Seng Lim...</p> <ul style="list-style-type: none"> • https://nadc.net.au/wp-content/uploads/2020/01/The-Role-of-General-Prac-in-IT-Education-for-Patients-Dr-Kean-Seng-Lim....pdf <p>The Role of Pharmacy in IT Education for Patients – Teresa Di Franco</p> <ul style="list-style-type: none"> • https://nadc.net.au/wp-content/uploads/2020/01/The-Role-of-Pharmacy-in-IT-Education-for-Patients-Teresa-Di-Franco.pdf
Driving	
ADEA Fitness to Drive	<p>The goal of the roll out of <i>the Support for Health Professionals in the assessment of a person with diabetes and their fitness to drive program</i> is to ensure a large percentage of health professionals are exposed to the online program and are aware of their obligations under AustRoad’s <i>Assessing Fitness to Drive for commercial and private drivers; Medical Standards for Licensing and Clinical Management Guidelines</i>.</p> <p>Templates have been developed to assist general practice in implementing discussions around diabetes and driving during consultations:</p> <p>https://members.adea.com.au/resources-2/fitness_to_drive/</p>
Assessing Fitness to Drive	<p>The National Transport Commission and Austroads have released <i>Assessing Fitness to Drive 2017</i>, a new edition of national medical standards for driver licensing. To view or download a copy, please click here</p> <p>https://austroads.com.au/publications/assessing-fitness-to-drive/ap-g56/foreword</p>
Driving and Diabetes in Australia Booklet	https://www.ndss.com.au/wp-content/uploads/resources/booklet-diabetes-and-driving.pdf
Driving and Recent Severe Hypoglycaemia Flyer	https://diabetessociety.com.au/downloads/Driving%20and%20Diabetes%20Flyer.pdf
ADS Position Statement on Insulin-requiring diabetes and recreation diving	https://diabetessociety.com.au/documents/ADS_Diving_Diabetes_2016_Final.pdf
Workplace	
An Employee’s Guide to Diabetes in the Workplace	<p>This booklet was developed in response to questions, concerns and suggestions Diabetes Australia received from members of the diabetes community about diabetes in the workplace.</p> <p>https://www.diabetesqld.org.au/media/42934/daq_employee_guide.pdf</p>

<p>Diabetes Victoria Diabetes in the Workplace</p>	<p>Diabetes Victoria have developed booklets about diabetes in the workplace for people with diabetes, their employees and co-workers.</p> <p>To access these booklets and additional information from Diabetes Victoria:</p> <p>https://www.diabetesvic.org.au/diabetes-and-me-type?tags=Left-Mega-Nav%2Fliving%20with%20diabetes%2FDiabetes%20in%20the%20workplace%2F&bdc=1</p> <ul style="list-style-type: none"> • An employer's guide to diabetes in the workplace (PDF) https://s3-ap-southeast-2.amazonaws.com/dv-resources/OrchestraCMS/a1f90000071gHsAAI.pdf • An employee's guide to diabetes in the workplace (PDF) https://s3-ap-southeast-2.amazonaws.com/dv-resources/OrchestraCMS/a1f90000071gHnAAI.pdf • Diabetes in the workplace: explanatory notes for health professionals (PDF) https://s3-ap-southeast-2.amazonaws.com/dv-resources/OrchestraCMS/a1f90000071gHiAAI.pdf • Diabetes in the workplace checklist (PDF) https://s3-ap-southeast-2.amazonaws.com/dv-resources/OrchestraCMS/a1f90000071gHdAAI.pdf
<p>NDSS</p>	
<p>Blood Glucose Test Strip Six Month Approval – NDSS</p>	<p>https://static.diabetesaustralia.com.au/s/fileassets/diabetes-australia/cb3d57f6-dc1a-40d3-b44b-c15a82c038cb.pdf</p>
<p>Medication Change Form – NDSS</p>	<p>https://static.diabetesaustralia.com.au/s/fileassets/diabetes-australia/5734f97b-1f62-42a2-a774-ae233a83eee6.pdf</p>
<p>Registration Form - NDSS</p>	<p>https://static.diabetesaustralia.com.au/s/fileassets/diabetes-australia/ce7d2178-f159-45c4-8b2b-1142622b84f4.pdf</p>
<p>Personal Details Update Form - NDSS</p>	<p>https://www.ndss.com.au/wp-content/uploads/forms/form-registration-update-your-personal-details.pdf</p>
<p>Insulin Pump Consumables Assessment Form –NDSS</p>	<p>https://www.ndss.com.au/wp-content/uploads/forms/insulin-pump-consumables-assessment-form.pdf</p>
<p>Continuous Glucose Monitoring Eligibility Assessment Form – NDSS</p>	<p>https://www.ndss.com.au/living-with-diabetes/managing-diabetes/continuous-glucose-monitoring/</p>
<p>Continuous Glucose Monitoring Update or Termination Form – NDSS</p>	<p>https://static.diabetesaustralia.com.au/s/fileassets/diabetes-australia/2332e950-1bf4-4ab5-990d-d7f8ba039958.pdf</p>
<p>Diabetes Related Organisations In Australia</p>	
<ul style="list-style-type: none"> • Australian Diabetes Society • Australian Diabetes Educators Association • Diabetes Australia • National Diabetes Services Scheme • National Association of Diabetes Centres 	
<p>Diabetes Australia Position Statements</p>	<p>To view or download all current Diabetes Australia position statements: https://www.diabetesaustralia.com.au/position-statements</p>

Australian Government Departments

- [Australian Department of Health](#)
 - BPDC 2016 Minister for Health Presentation – Priorities for the Government in Health can be viewed at <https://www.youtube.com/watch?v=w-0QRgDISS8>
- [Australian Institute of Health and Welfare](#)
- [Federation of Ethnic Communities Council Australia](#)
- [Healthdirect Australia](#)
- [Food Standards Australia and New Zealand](#)
- [Medicare Australia](#)
- [National Health and Medical Research Council \(NH&MRC\)](#)
- [Pharmaceutical Benefits Scheme](#)
- [Therapeutic Goods Administration](#)

Professional Associations & Organisations

- [Australian Diabetes Society \(ADS\)](#)
- [Australian Diabetes Educators Association \(ADEA\)](#)
- [Australian Practice Nurses Association \(APNA\)](#)
- [Australasian Diabetes In Pregnancy Society \(ADIPS\)](#)
- [Australasian Paediatric Endocrine Group \(APEG\)](#)
- [Australasian Podiatry Council](#)
- [Cancer Council Australia](#)
- [Dietitians Association of Australia](#)
- [National Heart Foundation](#)
- [Kidney Health Australia](#)
- [National Aboriginal Community Controlled Health Organisation](#)
- [National Stroke Foundation](#)
- [Optometrists Association of Australia](#)
- [Palliative Care Australia](#)
- [Pharmaceutical Society of Australia](#)
- [The Royal Australian College of General Practitioners](#)
- [Pharmacy Guild of Australia](#)

International Diabetes Associations

- [International Diabetes Federation](#)
- [American Diabetes Association](#)
- [Diabetes Canada](#)
- [Diabetes New Zealand](#)
- [Diabetes United Kingdom](#)
- [Glycosmedia](#)

Support

- [Children with Diabetes](#) (part of the Johnson & Johnson Diabetes Franchise)
- [Diabetes Counselling Online](#)
- [Diabetes and Emotional Health Handbook and Toolkit](#)

updated 04.02.2020

9. References

1. DO IT Study Group. Reports of the EASD Study Group DO IT 1990/1991. *Diabetologia*. 1991;34(Suppl 2):I-IX.
2. Krans HMJ, Porta M, Keen H. Monitoring instruments for quality improvement in diabetes care. *G Ital Diabetologia*. 1993;10:371-7.
3. Piwernetz K, Home PD, Snorgaard O, Antsiferov M, Staehr-Johansen K, Krans M. Monitoring the targets of the St Vincent Declaration and the implementation of quality management in diabetes care: the DIABCARE initiative. The DIABCARE Monitoring Group of the St Vincent Declaration Steering Committee. *Diabet Med*. 1993;10(4):371-7.
4. Piwernetz K, Bruckmeier A, Johansen KS, Krans HMJ. Diabcare Quality Network in Europe. *Diabetes Nutr Metab*. 1993;6(6):311-4.
5. Diabetes Australia NSW & NSW Department of Health. Report on the 1993 NSW Diabetes Outcomes Workshop (NDOW). NSW Department of Health; 1993.
6. Rattray A, Colagiuri S, Churches T, Flack JR. NSW diabetes outcomes workshop (NDOW) data collection. Proceedings of the Australian Diabetes Society Meeting, September 1995. 1998.
7. AIHW. National Health Priority Areas Report: Diabetes Mellitus 1998.: Canberra ACT: Commonwealth Department of Health and Aged Care, and the Australian Institute of Health and Welfare.; 1999.
8. Meteor metadata online registry. Diabetes (clinical) NBPDS Canberra ACT: Australian Institute of Health and Welfare; 2005 [Available from: <https://meteor.aihw.gov.au/content/index.phtml/itemId/304865>].
9. Fleming BB, Greenfield S, Engelgau MM, Pogach LM, Clauser SB, Parrott MA. The Diabetes Quality Improvement Project: moving science into health policy to gain an edge on the diabetes epidemic. *Diabetes Care*. 2001;24(10):1815-20.
10. Quality and efficiency of diabetes care in Sweden: National performance assessment. NBHW, Stockholm Sweden. 2011 May 18. Contract No. 2014-3-18.
11. NICE quality and outcomes framework indicator: diabetes mellitus London, UK [Available from: <https://www.nice.org.uk/standards-and-indicators/qofindicators?categories=&page=2>].